[Ip-health] Patents on Ritonavir, the August 16, 2011 WIPO Study

Mailander, Lutz Lutz.Mailander at wipo.int
Fri Oct 21 00:06:53 PDT 2011


Thank you for the attention given to our report on Ritonavir.

I may add to the below statement on the 805 "patents":

It is 805 patent families. The excel table that comes with the report includes also all INPADOC family members, ie the extensions to various jurisdictions. Some families comprise many such extensions. There is also a link to Espacenet where you can easily look up the up-to-date INAPADOC family information.

We selected all such families that somehow claim inventive subject matter related to Ritonavir, ie the substance is an essential component of the subject matter defined by the claims. Patents just mentioning it as an example among other options or just mentioning it in the description were not included.

We would like to invite comments on the correctness of the list of researched patents or other observations.

I would also like to draw your attention to the very detailed explanation of the search methodology.

Following a request from DNDI, we have commissioned an add-on for identifying among the 805 all the prodrug related patents. It may be ready in about 6 weeks.

We will shortly publish a second report on Atanazavir.


Bes regards

Lutz Mailänder

Head Patent Information Section
Global IP Infrastructure Sector
WIPO - World Intellectual Property Organization

34, chemin des Colombettes
1211 Geneva 20 - Switzerland
+41 22 338 9849




-----Original Message-----
From: ip-health-bounces at lists.keionline.org [mailto:ip-health-bounces at lists.keionline.org] On Behalf Of Jamie Love
Sent: jeudi, 20. octobre 2011 14:18
To: Ip-health
Subject: [Ip-health] Patents on Ritonavir, the August 16, 2011 WIPO Study

A few days ago, I posted a link to a KEI blog about "USPTO issued patents
mentioning ritonavir in the patent claim."
http://www.keionline.org/node/1297.   I have since expanded the KEI blog
entry, for example, by identifying 42 patents connected to the NIH contract
that led to the development of ritonavir, and the 11 additional patents with
Bayh-Dole Act rights associated with them.

In my blog I simply looked at the 236 patents that either cited ritonivir in
the patent clams (194) or that mentioned the NIH contract (42).  Esteban
Burrone subcalled my attention to the August 16, 2011 WIPO study on the
patent landscape by Landon IP, which is available here:
http://www.wipo.int/patentscope/en/programs/patent_landscapes/reports/ritonavir.html.
 According to the WIPO/Landon study:

"There have been over 800 patents filed since the initial PCT application
WO1994014436 to protect different aspects of Ritonavir and its methods of
use. A large number of documents filed subsequent to the initial application
still protect the structure of Ritonavir as described in the initial
application. As one would suspect, subsequent patent filings continue to
narrow the focus of protection of Ritonavir by incorporating novel aspects
to the subject of Ritonavir. The implications of patent protection are
important for developing countries to consider. Simply licensing the initial
key documents will not provide adequate freedom to operate because of the
breadth of coverage by subsequent patents."

There are all sorts of policy and health ramifications associated with the
proliferation of patents on ritionavir, including of course, a deeper
appreciation for why it is important that countries reject efforts in trade
agreements to shrink national flexibility on standards for granting patents.
  Many of these patents do not meet the higher standards for granting
pharmaceutical patents in India, for example, but do qualify in many other
countries, both developed and developing.  This is a topic that will be
discussed in the TPPA negotiations this month in Peru, where President Obama
and USTR will push their proposal to mandate granting more patents,
including by imposing this new obligation on TPPA member countries such as
Vietnam, Peru, Thailand, Malaysia, and Chile:

"In addition, the Parties confirm that: patents shall be available for any
new forms, uses, or methods of using a known product; and a new form, use,
or method of using a known product may satisfy the criteria for
patentability, even if such invention does not result in the enhancement of
the known efficacy of that product."

The WIPO study also sheds some light on the potential benefits of the
Medicines Patent Pool licenses for patents on cobicistat, a new Gilead drug
that is expected to offer similar benefits to ritonavir.

These are the 805 patents that WIPO says "protect different aspects of
Ritonavir and its methods of use."

Number, Publication Year, Assignee, Title
WO1994014436, 1994, ABBOTT LAB, RETROVIRAL PROTEASE INHIBITING COMPOUNDS
WO1989010752, 1989, ABBOTT LAB, RETROVIRAL PROTEASE INHIBITORS
WO1992008701, 1992, MONSANTO CO | SEARLE & CO, RETROVIRAL PROTEASE
INHIBITORS
EP0490667, 1992, JAPAN ENERGY CORPORATION, HIV protease inhibitors.
WO1993009096, 1993, MERCK & CO INC, HIV PROTEASE INHIBITORS USEFUL FOR THE
TREATMENT OF AIDS
WO2002097114, 2002, RIBOZYME PHARMACEUTICALS, INC, NUCLEIC ACID TREATMENT OF
DISEASES OR CONDITIONS RELATED TO LEVELS OF RAS, HER2 AND HIV
WO1995006061, 1995, MONSANTO CO | SEARLE & CO, RETROVIRAL PROTEASE
INHIBITORS AND COMBINATIONS THEREOF
WO1995007696, 1995, ABBOTT LAB, PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE
INHIBITORS
WO1995009614, 1995, ABBOTT LAB, PHARMACEUTICAL COMPOSITION
WO1995011224, 1995, ABBOTT LAB, PROCESS FOR THE PREPARATION OF A SUBSTITUTED
2,5-DIAMINO-3-HYDROXYHEXANE
WO1995020384, 1995, ABBOTT LAB, PHARMACEUTICAL COMPOSITIONS CONTAINING HIV
PROTEASE INHIBITORS
WO1995023793, 1995, DAICEL CHEMICAL INDUSTRIES, 2-ISOXAZOLINE DERIVATIVE AND
PROCESS FOR PRODUCING THE SAME  AND PROCESS FOR PRODUCING RELATED
DERIVATIVES FROM THE SAME
WO1995033464, 1995, SEARLE & CO, RETROVIRAL PROTEASE INHIBITOR COMBINATIONS
WO1996004232, 1996, ABBOTT LAB, PROCESS FOR THE PREPARATION OF A SUBSTITUTED
2.5-DIAMINO-3-HYDROXYHEXANE
WO1998038193, 1998, SARAWAK MEDICHEM PHARMACEUTICALS, METHOD FOR THE
PREPARATION OF (+)-CALANOLIDE A AND ANALOGUES THEREOF
WO1996004913, 1996, MERCK & CO INC, HIV PROTEASE INHIBITOR COMBINATION
WO1996026734, 1996, GSK LLC, ANTIVIRAL COMBINATIONS OF BCH-189 AND RITONAVIR
EP0728481, 1996, BAYER AG, Use of quinoxaline and protease inhibitors in a
composition for the treatment of AIDS and/or HIV infections
WO1996026934, 1996, UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, SYNTHESIS
OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED
COMPOUNDS
WO1999059585, 1999, ARISYN THERAPEUTICS, INC, COMPOSITIONS FOR THE TREATMENT
OF HIV AND OTHER VIRAL INFECTIONS
WO1996039398, 1996, ABBOTT LAB, PROCESS FOR THE PREPARATION OF AN HIV
PROTEASE INHIBITING COMPOUND
WO1997001349, 1997, ABBOTT LAB, USE OF RITONAVIR (ABT-538) FOR IMPROVING THE
PHARMACOKINETICS OF DRUGS METABOLIZED BY CYTOCHROME P450 IN A METHOD OF
TREATING AIDS
WO1997021685, 1997, ABBOTT LAB, RETROVIRAL PROTEASE INHIBITING COMPOUNDS
WO1997027180, 1997, VERTEX PHARMA, ASPARTYL PROTEASE INHIBITORS
WO1997027480, 1997, VIRCO NV, METHOD OF MANAGING THE CHEMOTHERAPY OF
PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF
HUMAN HIV STRAINS
WO1997027856, 1997, SANKYO COMPANY LIMITED, | UBE INDUSTRIES LTD, REMEDIES
OR PREVENTIVES FOR AIDS
WO1997035587, 1997, GSK LLC, COMPOSITIONS COMPRISING AN HIV PROTEASE
INHIBITOR SUCH AS VX 478 AND A WATER SOLUBLE VITAMIN E COMPOUND SUCH AS
VITAMIN E-TPGS
WO1997037657, 1997, SHIONOGI & CO., LTD, ANTI-HIV COMPOSITION CONTAINING
IMIDAZOLE DERIVATIVE
WO1997042962, 1997, INFECTIO RECHERCHE, INC., FORMULATION FOR USE IN THE
PREVENTION OF PATHOGEN INDUCED DISEASES INCLUDING HIV AND HSV
WO1997046222, 1997, MERCK & CO INC, PEDIATRIC FORMULATION FOR HIV PROTEASE
INHIBITORS
WO1998000393, 1998, ABBOTT LAB, PROCESS FOR THE PREPARATION OF AN ACTIVATED
AMINO ACID
WO1998000410, 1998, ABBOTT LAB, PROCESS FOR THE PREPARATION OF A
DISUBSTITUTED THIAZOLE
WO1998003476, 1998, NOVARTIS AG, ANILINOPEPTIDE DERIVATIVES
WO1998004290, 1998, BOSTON UNIVERSITY TRUSTEES, COMPOSITIONS COMPRISING AN
INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND
CELLULAR DISORDERS
US5905068, 1999, ABBOTT LAB, Retroviral protease inhibiting compounds
WO1998014436, 1998, BRISTOL MYERS SQUIBB PHARMA CO,
4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE
TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME
US5874430, 1999, BRISTOL MYERS SQUIBB PHARMA CO,
4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse
transcriptase inhibitors and intermediates and processes for making the same
WO1998017282, 1998, VERTEX PHARMA, METHODS OF USING SUCROSE OCTASULFATE TO
TREAT OR PREVENT ENVELOPED VIRUS INFECTION
WO1998020009, 1998, BRISTOL MYERS SQUIBB PHARMA CO,
(4R,5S,6S,7R)-HEXAHYDRO-1- [5-(3-AMINOINAZOLE)METHYL]
-3-BUTYL-5,6-DIHYDROXY-4,7-BIS [PHAENYLMETHYL] -2H-1,3-DIAZEPIN-2-ONE, ITS
PREPARATION AND ITS USE AS HIV PROTEASE INHIBITOR
WO1998020888, 1998, JAPAN ENERGY CORPORATION, AIDS REMEDY
US6232333, 2001, ABBOTT LAB, Pharmaceutical composition
WO1998022106, 1998, ABBOTT LAB, PHARMACEUTICAL COMPOSITION
WO1998028330, 1998, AVENTIS PHARMA S.A, NOVEL CYCLOSPORIN DERIVATIVES,
METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1998033067, 1998, UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,
TRANSCRIPTION FACTORS THAT REPRESS HIV TRANSCRIPTION AND METHODS BASED
THEREON
WO1998032442, 1998, BAYER AG, QUINOXALINE IN TRIPLE COMBINATION WITH
PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR
TREATING AIDS
WO1998035666, 1998, NANOSYSTEMS LLC, FORMULATIONS OF NANOPARTICLE NAPROXEN
TABLETS
WO2009120240, 2009, DEXCOM INC, ANALYTE SENSOR
WO2007134037, 2007, IMMUNOMEDICS INC, METHODS AND COMPOSITIONS FOR TREATMENT
OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH CONJUGATED ANTIBODIES OR
ANTIBODY FRAGMENTS
WO1998043969, 1998, BRISTOL MYERS SQUIBB PHARMA CO, INDAZOLES OF CYCLIC
UREAS USEFUL AS HIV PROTEASE INHIBITORS
WO1998045276, 1998, BRISTOL MYERS SQUIBB PHARMA CO,
4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINONES USEFUL AS HIV REVERSE
TRANSCRIPTASE INHIBITORS
WO1998046241, 1998, TRIAD BIOTHERAPEUTICS, INC., A COMBINATION THERAPY FOR
HIV INFECTIONS
WO1998047492, 1998, VERTEX PHARMA, NANOSIZED ASPARTYL PROTEASE INHIBITORS
WO1998048021, 1998, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, KAPOSI'S
SARCOMA HERPESVIRUS (HHV8) PROTEASE AND ASSEMBLY PROTEIN
WO1998052571, 1998, GSK LLC, ANTIVIRAL COMBINATIONS CONTAINING THE
CARBOCYCLIC NUCLEOSIDE 1592U89
WO2006017341, 2006, UMD, INC, COATED VAGINAL DEVICES FOR VAGINAL DELIVERY OF
THERAPEUTICALLY EFFECTIVE AND/ OR HEALTH-PROMOTING AGENTS
WO1998057648, 1998, VERTEX PHARMA, METHODS OF INCREASING THE BIOAVAILABILITY
OF STABLE CRYSTAL POLYMORPHS OF A COMPOUND
WO1999009005, 1999, CYTOKINE PHARMASCIENCES INC, HIV MATRIX PROTEIN TYROSINE
POSITION 29 POCKET BINDERS
WO1999008676, 1999, WARNER LAMBERT CO | HE KAN | HOLLENBERG PAUL | WOOLF
THOMAS F, COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL
BIOAVAILABILITY OF PHARMACEUTICAL AGENTS
WO1999011635, 1999, BRISTOL MYERS SQUIBB PHARMA CO,
5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV
REVERSE TRANSCRIPTASE INHIBITORS
WO1999012569, 1999, ALCAFLEU MANAGEMENT GMBH & CO, METHODS FOR INCREASING
CD4
WO2002095005, 2002, GENETIC IMMUNITY, LLC, THERAPEUTIC DNA VACCINATION
WO1999013914, 1999, SICOR INC., PHARMACEUTICAL COMPOSITIONS CONTAINING
PLASMA PROTEIN
WO1999025352, 1999, MERCK & CO INC, COMBINATION THERAPY FOR THE TREATMENT OF
AIDS
US6040434, 2000, INABA TADANOBU | FAYZ SHIRIN | STEWART DAVID JOHN, Aldehyde
oxidase inhibitors for treatment of aids
WO1999029297, 1999, ALZA CORP, OSMOTIC DOSAGE FORM COMPRISING FIRST AND
SECOND COATS
EP1112741, 2001, BIOVAIL TECHNOLOGIES LTD, Use of protease inhibitors for
the treatment of necrotizing infections
WO2000010965, 2000, TAKEDA PHARMACEUTICAL COMPANY, QUATERNARY AMMONIUM SALTS
AND THEIR USE
WO1999033815, 1999, VERTEX PHARMA, SULPHONAMIDE DERIVATIVES AS PRODRUGS OF
ASPARTYL PROTEASE INHIBITORS
WO1999036406, 1999, MEDIVIR AB, ANTIVIRALS
FR2773994, 1999, UNIVERSITE DE NICE SOPHIA ANTIPOLIS, New human
immunodeficiency virus protease inhibitor prodrugs for inhibiting viral
proliferation in central nervous system - comprising protease inhibitor
coupled to substance that improves bioavailability, targeting and/ or
delivery to CNS
WO2001010454, 2001, DEFIANTE FARMACEUTICA, S.A, COMPOSITION AND METHODS FOR
TREATMENT OF HIV INFECTION
WO1999045025, 1999, MYRIAD PHARMACEUTICALS, INC, ACYLATED BETULIN AND
DIHYDROBETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
WO1999047146, 1999, RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY,
ANTI-HIV COMBINATION COMPRISING HYDROXYUREA, DDI, AND A PROTEASE INHIBITOR
WO1999048504, 1999, RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY,
COMPOSITIONS FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS USING HYDROXYUREA
AND A REVERSE TRANSCRIPTASE INHIBITOR
WO1999048526, 1999, RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY, METHOD
OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION
INCOMPETENT IN VIVO
WO1999050253, 1999, BRISTOL MYERS SQUIBB PHARMA CO,
4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINTHIONE DERIVATIVES, THEIR
PREPARATION AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO1999051203, 1999, DRUGTECH CORPORATION, MAXIMIZING EFFECTIVENESS OF
SUBSTANCES USED TO IMPROVE HEALTH AND WELL BEING
WO2000052034, 2000, BIO HOLDING, INC, INHIBITORS OF SERINE PROTEASE
ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS
WO1999055843, 1999, HEMOSOL INC, EFFICIENT EX VIVO EXPANSION OF CD4<+> AND
CD8<+> T-CELLS FROM HIV INFECTED SUBJECTS
WO1999055370, 1999, ALCAFLEU MANAGEMENT GMBH & CO, METHODS FOR REDUCING HIV
VIRAL LOAD BY ADMINISTERING GM-CSF AND ANTIRETROVIRAL AGENTS
US6251906, 2001, ABBOTT LAB, Retroviral protease inhibiting compounds
US6558923, 2003, PASTEUR INSTITUT, Rapid single-cycle assay for human
immunodeficiency virus type 1 drug resistance
WO1999064001, 1999, GSK LLC, METHODS AND COMPOSITIONS FOR INCREASING
PENETRATION OF HIV PROTEASE INHIBITORS
WO1999063998, 1999, INSTITUT NATIONAL DE SANTE ET DE LA RECHERCHE MEDI |
BIOMERIEUX, NOVEL USE OF HIV PROTEASE INHIBITING COMPOUNDS
WO1999065870, 1999, VERTEX PHARMA, SULFONAMIDE INHIBITORS OF ASPARTYL
PROTEASE
WO1999067417, 1999, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH, FITNESS ASSAY AND ASSOCIATED METHODS
WO1999066936, 1999, NOVIRIO PHARMACEUTICALS LIMITED, USE OF
3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR
THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV
WO2000000478, 2000, BRISTOL MYERS SQUIBB PHARMA CO, SUBSTITUTED
QUINOXALIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2000000475, 2000, BRISTOL MYERS SQUIBB PHARMA CO, SUBSTITUTED
QUINOLIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2000000479, 2000, BRISTOL MYERS SQUIBB PHARMA CO, 1,3-BENZODIAZEPIN-2-ONES
AND 1,3-BENZOXAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2006041538, 2006, ORYXE ENERGY INTERNATIONAL, INC., A MIXTURE FOR
TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS
WO2000003998, 2000, NOVIRIO PHARMACEUTICALS LIMITED, SUBSTITUTED
6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM
WO2000004033, 2000, GSK LLC, CALCIUM (3S)
TETRAHYDRO-3-FURANYL(1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]
-1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE
US7148359, 2006, ABBOTT LAB, Polymorph of a pharmaceutical
WO2000004016, 2000, ABBOTT LAB, POLYMORPH OF A PHARMACEUTICAL
WO200156547, 2006, YOO SEO HONG   US, PREPARATION OF AQUEOUS CLEAR SOLUTION
DOSAGE FORMS WITH BILE ACIDS
WO2000006143, 2000, ST. JUDE PHARMACEUTICALS, INC., CHEMICALLY INDUCED
INTRACELLULAR HYPERTHERMIA
WO2000009150, 2000, PRENDERGAST PATRICK T, CYTOKINE AND CYTOKINE RECEPTOR,
AGONIST, ANTAGONIST AND/OR ANTIBODY COMBINATION FOR THERAPEUTIC USE
WO2000021514, 2000, SARAWAK MEDICHEM PHARMACEUTICALS, METHOD AND COMPOSITION
FOR TREATING AND PREVENTING TUBERCULOSIS
WO2000025784, 2000, UPJOHN CO., METHOD FOR IMPROVING THE PHARMACOKINETICS OF
TIPRANAVIR
WO2000025799, 2000, L'UNIVERSITE MONTPELLIER II | EMORY UNIVERSITY | CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFQUE, beta -L-2'-DEOXY-NUCLEOSIDES FOR THE
TREATMENT OF HIV INFECTION
WO2000027196, 2000, SCHERING CORP, USE OF GM-CSF TO INHIBIT DEVELOPMENT OF
DRUG RESISTANCE IN HIV<+> PATIENTS
WO2000035472, 2000, HOLLIS EDEN PHARMACEUTICALS, CYTOKINE COMBINATION
THERAPY
WO2000033654, 2000, UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE, USE OF
PROTEASE INHIBITORS TO MODULATE CELLULAR PATHWAYS, IMMUNITY AND THERAPIES
ASSOCIATED THEREWITH
WO2000035419, 2000, ENCINAL PHARMACEUTICAL INVESTMENTS, LLC, CONVERSION OF
LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE
COATINGS
WO2000037455, 2000, TAKEDA PHARMACEUTICAL COMPANY, BENZOTHIEPIN-ANILIDE
DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5
WO2000039143, 2000, BIOCHEM PHARMA INC, ANTIVIRAL NUCLEOSIDE ANALOGUES
WO2000038650, 2000, ENCINAL PHARMACEUTICAL INVESTMENTS, LLC, GASTRIC
RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS
WO2000038680, 2000, PFIZER, AZABICYCLOALKANES AS CCR5 MODULATORS
WO2000038679, 2000, VIRAL AS, TREATMENT OF RETROVIRAL INFECTIONS WITH
OXYPHENBUTAZONE
WO2005039587, 2005, 4 AZA BIOSCIENCE NV, HETEROCYCLE-SUBSTITUTED PTERIDINE
DERIVATIVES AND THEIR USE IN THERAPY
WO2000040269, 2000, LEE CLARENCE C | LEE FENG MIN, PHARMACEUTICAL
COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES
WO2000042060, 2000, BRISTOL MYERS SQUIBB PHARMA CO, BIS-AMINO ACID
SULFONAMIDES CONTAINING N-TERMINALLY A SUBSTITUTED BENZYL GROUP AS HIV
PROTEASE INHIBITORS
WO2000043017, 2000, SAMARITAN PHARMACEUTICALS INC., COMPOSITION OF ANTI-HIV
DRUGS AND ANTI-CORTISOL COMPOUNDS AND METHOD FOR DECREASING THE SIDE EFFECTS
OF ANTI-HIV DRUGS IN A HUMAN
WO2004025267, 2004, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, METHOD FOR
TESTING DRUG SUSCEPTIBILITY OF HIV
WO2004104005, 2004, 4 AZA BIOSCIENCE NV, IMMUNOSUPPRESSIVE EFFECTS OF
PTERIDINE DERIVATIVES
WO2000047561, 2000, MEDIVIR AB, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS
WO2000050043, 2000, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, METHODS OF
TREATMENT OF MITOCHONDRIAL DISORDERS
WO2004032718, 2004, TACT IP, LLC, CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND
NEUROPSYCHIATRIC DISORDERS
US6440946, 2002, TAKEDA PHARMACEUTICAL COMPANY, Multiple-agents-binding
compound, production and use thereof
WO2007018943, 2007, LIPOCINE INC | PATEL MAHESH, SOLID CARRIERS FOR IMPROVED
DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS
WO2000051641, 2000, BIOCHEM PHARMA INC, PHARMACEUTICAL COMBINATION OF
ANTIVIRAL AGENTS
WO2003020200, 2003, NEW RIVER PHARMACEUTICALS INC, A NOVEL PHARMACEUTICAL
COMPOUND AND METHODS OF MAKING AND USING SAME
WO2000056303, 2000, IMMUGEN PHARMACEUTICALS INC, TREATMENT OF IMMUNE
DISEASES
WO2000056729, 2000, GENZYME CORPORATION, CHEMOKINE RECPETOR BINDING
HETEROCYCLIC COMPOUNDS
WO2000059475, 2000, LIPOCINE INC, COMPOSITIONS AND METHODS FOR IMPROVED
DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS
WO2000059486, 2000, PFIZER, USE OF CYP2D6 INHIBITORS IN COMBINATION
THERAPIES
WO2000066551, 2000, TAKEDA PHARMACEUTICAL COMPANY, CYCLIC AMIDE COMPOUNDS,
PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF
WO2000066173, 2000, INFECTIO RECHERCHE INC., METHODS AND FORMULATIONS FOR
TARGETING INFECTIOUS AGENTS BEARING HOST CELL PROTEINS
US6602885, 2003, SCHERING CORP, Piperidine derivatives useful as CCR5
antagonists
WO2000066559, 2000, SCHERING CORP, PIPERIDINE DERIVATIVES USEFUL AS CCR5
ANTAGONISTS
WO2007050375, 2007, SCHERING CORP, PIPERAZINE DERIVATIVES USEFUL AS CCR5
ANTAGONISTS
WO2000067801, 2000, UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, PERMEABLE,
WATER SOLUBLE, NON-IRRITATING PRODRUGS OF CHEMOTHERAPEUTIC AGENTS WITH
OXAALKANOIC ACIDS
WO2000068203, 2000, TAKEDA PHARMACEUTICAL COMPANY, CYCLIC COMPOUNDS AND USES
THEREOF
WO2000069255, 2000, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,
ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION
WO2000073284, 2000, BRISTOL MYERS SQUIBB PHARMA CO, 1,4-BENZODIAZEPIN-2-ONES
USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2000072827, 2000, ACUSPHERE, INC, POROUS DRUG MATRICES AND METHODS OF
MANUFACTURE THEREOF
US7141593, 2006, ABBOTT LAB, Pharmaceutical formulations
WO2000074677, 2000, ABBOTT LAB, IMPROVED PHARMACEUTICAL FORMULATIONS
WO2000076961, 2000, ERTEX PHARMACEUTICALS INCORPORATED, INHIBITORS OF
ASPARTYL PROTEASE
WO2000076993, 2000, TAKEDA PHARMACEUTICAL COMPANY, BENZAZEPINE DERIVATIVES,
PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF
WO2002099387, 2002, VIROLOGIC INC, MEANS AND METHODS FOR MONITORING PROTEASE
INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE
TREATMENT OF HIV/AIDS
WO2001068086, 2001, UNIVERSITAIR MEDISCH CENTRUM UTRECHT, ANTIVIRAL THERAPY
WO2003045404, 2003, CANCER2 INC, METHODS FOR REGULATING LEVELS OF ZINC,
CADMIUM AND CALCIUM IN HUMANS AND FOR DIAGNOSING, OR SCREENING FOR THE RISK
OF DEVELOPING, DISEASES ASSOCIATED WITH ABNORMAL LEVELS OF CADMUIM, ZINC AND
CALCIUM IN BODY FLUIDS AND TISSUES
WO2004004660, 2004, ALPHA RESEARCH GROUP, COMPOSITIONS AND METHODS FOR THE
TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS
AU2007202956, 2007, ABBOTT LAB, Polymorph of a pharmaceutical
IT1313575, 2001, RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A, SOLID
DRUGGIST PREPARATIONS OF RITONAVIR FOR ORAL USE
WO2001010387, 2001, VANDERBILT UNIVERSITY, ANTIVIRAL THERAPY USE OF
P-GLYCOPROTEIN MODULATORS
WO2001012168, 2001, FACULTEIT GENEESKUNDE UNIVERSITEIT UTRECHT,
PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR
OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)
WO2001021603, 2001, ARCHIMICA S.R.L., A PROCESS FOR THE SYNTHESIS OF
RITONAVIR
WO2001025200, 2001, TAKEDA PHARMACEUTICAL COMPANY, CYCLIC AMINE COMPOUNDS AS
CCR5 ANTAGONISTS
WO2003053347, 2003, BERNSTEIN LAWRENCE R, GALLIUMCOMPLEXES OF
3-HYDROXY-4-PYRONES TO TREAT MYCOBACTERIAL INFECTIONS
WO2001025199, 2001, TAKEDA PHARMACEUTICAL COMPANY, UREA COMPOUNDS, PROCESS
FOR PRODUCING THE SAME AND USE THEREOF
WO2001025240, 2001, TIBOTEC PHARM LTD, HEXAHYDROFURO'2,3-B!FURAN-3-YL-N-
{3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO!
-1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR
WO2001026467, 2001, ONTOGEN CORP | NEWMAN MICHAEL JAMES | DIXON WILLIAM
ROSS, METHODS OF ENHANCING CHEMOTHERAPY
WO2001028555, 2001, LIPOCINE INC, EMULSION COMPOSITIONS FOR POLYFUNCTIONAL
ACTIVE INGREDIENTS
WO2001029037, 2001, BRISTOL MYERS SQUIBB PHARMA CO, TRICYCLIC COMPOUNDS
USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2001028532, 2001, KAIN KEVIN C | SERGHIDES LENA, METHODS AND COMPOSITIONS
FOR PREDICTING, DIAGNOSING AND TREATING LIPODYSTROPHY
US7364752, 2008, ABBOTT LAB, Solid dispersion pharamaceutical formulations
WO2001034118, 2001, ABBOTT LAB, SOLID DISPERSION PHARMACEUTICAL FORMULATIONS
WO2001034119, 2001, ABBOTT LAB, INHIBITORS OF CRYSTALLIZATION IN A SOLID
DISPERSION
WO2001038332, 2001, MERCK & CO INC,
GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV
PROTEASE INHIBITORS
WO2001041742, 2001, ALZA CORP, ANTIVIRAL MEDICATION
WO2001044508, 2001, BIOSTRANDS S.R.L., METHOD TO EVALUATE THE HIV DRUG
SENSITIVITY
WO2001047511, 2001, UNIVERSITY OF PITTSBURGH | REGENTS OF THE UNIVERSITY OF
CALIFORNIA, TREATMENT OF DRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS
INFECTION
WO2001049700, 2001, BIOCHEM PHARMA INC, IMIDAZOPYRIMIDINE NUCLEOSIDE
ANALOGUES WITH ANTI-HIV ACTIVITY
WO2002102169, 2002, FOAMIX LTD, SYNTHETIC FAT COMPOSITION
US6391919, 2002, BRISTOL MYERS SQUIBB PHARMA CO, Bis-amino acid sulfonamides
containing substituted benzyl amines HIV protease inhibitors
WO2001050987, 2001, FIRST CIRCLE MEDICAL, INC, TREATMENT OF HEPATITIS C
USING HYPERTHERMIA
WO2001052821, 2001, ABBOTT LAB, IMPROVED PHARMACEUTICAL FORMULATIONS
EP1125936, 2001, PFIZER, Aryl substituted azabenzimidazoles and their use in
the treatment of HIV and AIDS related diseases
WO2001054729, 2001, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH, TREATMENT OF NEUROPSYCHIATRIC DISEASE WITH
PROTEASE AND NEURAMINIDASE INHIBITORS
WO2001054652, 2001, RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY, A
METHOD OF INDUCING AUTOVACCINATION AGAINST HIV INFECTION USING STRUCTURED
TREATMENT INTERRUPTIONS
WO2001066123, 2001, YALE UNIVERSITY, HERBAL COMPOSITION PHY906 AND ITS USE
IN CHEMOTHERAPHY
US20010041706, 2001, CITY OF HOPE, Blockade of taxane metabolism
WO2002077290, 2002, CITY OF HOPE, METHODS FOR MODIFYING PHARMACOKINETICS AND
BIOAVAILABILITY OF EXOGENOUS COMPOUNDS
WO2001074787, 2001, ABBOTT LAB, CRYSTALLINE PHARMACEUTICAL
WO2001079246, 2001, PHARMASSET, INC., 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED
NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS
WO2001078681, 2001, ASTELLAS PHARMA INC., DRUG DELIVERY SYSTEM FOR AVOIDING
PHARMACOKINETIC INTERACTION BETWEEN DRUGS AND METHOD THEREOF
WO2001080896, 2001, ARCH DEVELOPMENT CORPORATION, FLAVOPIRIDOL DRUG
COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS
WO2001082919, 2001, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH, METHODS OF AND COMPOUNDS FOR INHIBITING
CALPAINS
WO2001092288, 2001, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
REGENTS OF THE UNIVERSITY OF MINNESOTA, COBALAMIN COMPOUNDS USEFUL AS
ANTIBIOTIC AGENTS AND AS IMAGING AGENTS
WO2001094645, 2001, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW
YORK, TWO-HYBRID ASSAY THAT DETECTS HIV-1 REVERSE TRANSCRIPTASE DIMERIZATION
WO2002033638, 2002, VIRCO BVBA, NEW MUTATIONAL PROFILES IN HIV-1 REVERSE
TRANSCRIPTASE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE
WO2001096329, 2001, SHIONOGI & CO., LTD, MEDICINAL COMPOSITIONS CONTAINING
PROPENONE DERIVATIVES
EP1166782, 2002, TSAI HSIU HSIEN | TSAI SHIOU REN | YANG CHI CHIANG,
ANTI-RETROVIRAL Pharmaceutical compositions
WO2001097749, 2001, KOTZE GAVIN SALOMON | PRENDERGAST PATRICK THOMAS, THE
USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS, DERIVATIVES, METABOLITES
AND PRECURSORS THEREOF IN THE TREATMENT OF VIRAL INFECTIONS
WO2002000168, 2002, SUPERGEN INC., COMBINATION HIV THERAPY INCLUDING
CAMPTOTHECIN
WO2002003879, 2002, FIRST CIRCLE MEDICAL, INC, TREATMENT OF HIV USING
HYPERTHERMIA
WO2002003886, 2002, FIRST CIRCLE MEDICAL, INC, TREATMENT OF HUMAN
HERPESVIRUSES USING HYPERTHERMIA
WO2002006190, 2002, BRISTOL MYERS SQUIBB PHARMA CO, CRYSTALLINE AND SALT
FORMS OF AN HIV PROTEASE INHIBITOR
WO2002010124, 2002, BRISTOL MYERS SQUIBB PHARMA CO, SALT FORMS OF AN HIV
PROTEASE INHIBITOR
WO2002006292, 2002, BRISTOL MYERS SQUIBB PHARMA CO, PHOSPHATE ESTERS OF
BIS-AMINO ACID SULFONAMIDES CONTAINING SUBSTITUTED BENZYL AMINES
WO2002061798, 2002, ANALYTICA OF BRANDFORD INC, CHARGED PARTICLE TRAPPING IN
NEAR SURFACE POTENTIAL WELLS
US6911214, 2005, ABBOTT LAB, Flavoring systems for pharmaceutical
compositions and methods of making such compositions
WO2002020057, 2002, ABBOTT LAB, FLAVORING SYSTEMS FOR PHARMACEUTICAL
COMPOSITIONS AND METHODS OF MAKING SUCH COMPOSITIONS
WO2003085127, 2003, TELIK, INC., METHOD FOR IDENTIFICATION OF INSULIN
RECEPTOR KINASE ACTIVATORS
WO2002034284, 2002, CHIRON CORPORATION, METHODS OF THERAPY FOR HIV INFECTION
WO2002033402, 2002, VIRCO BVBA, ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES
FOR PREDICTING RESISTANCE TO THERAPY
EP1207394, 2002, F. HOFFMANN-LA ROCHE AG, Immunoassay for HIV protease
inhibitors
WO2002056902, 2002, SCHERING CORP, COMBINATION METHOD FOR TREATING VIRAL
INFECTIONS
US6623761, 2002, HASSAN EMADELDIN M, Method of making nanoparticles of
substantially water insoluble materials
WO2002053138, 2002, SHANAHAN-PRENDERGAST ELISABETH, TREATMENT FOR INHIBITING
NEOPLASTIC LESIONS
WO2002056861, 2002, INTELLIPHARMACEUTICS INC., SYNTACTIC DEFORMABLE FOAM
COMPOSITIONS AND METHODS FOR MAKING

WO2002062123, 2002, YALE UNIVERSITY | UNIVERSITY OF GEORGIA RESEARCH
FOUNDATION, INC, NOVEL COMPOUNDS AND METHODS FOR INHIBITING/TREATING HIV
INFECTIONS AND AIDS RELATED SYMPTOMS
WO2002070070, 2002, PFIZER, COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY
WO2002070470, 2002, GSK LLC, BENZOPHENONES AS INHIBITORS OF REVERSE
TRANSCRIPTASE
WO2002072109, 2002, PANACOS PHARMACEUTICALS INC | THE UNIVERSITY OF NORTH
CAROLINA AT CHAPEL HILL, SUBSTITUTED
3',4'-DI-O-CAMPHANOYL-(+)-CIS-KHELLACTONE ANALOGS,   COMPOSITIONS THEREOF,
AND METHODS FOR USING THEREOF
WO2002074777, 2002, SARAWAK MEDICHEM PHARMACEUTICALS, PYRANOCOUMARIN
COMPOUNDS AS A NOVEL PHARMACOPHORE WITH ANTI-TB ACTIVITY
WO2007022255, 2007, GSK LLC, PHARMACEUTICAL FORMULATIONS FOR SUSTAINED
RELEASE
WO2002078628, 2002, BRISTOL MYERS SQUIBB PHARMA CO, CYANAMIDE, ALKOXYAMINO,
AND UREA DERIVATIVES OF 1,3-BENZODIAZAPINES AS HIV REVERSE TRANSCRIPTASE
INHIBITORS
WO2002081456, 2002, BRISTOL MYERS SQUIBB PHARMA CO, CYANAMIDE, ALKOXYAMINO,
AND UREA DERIVATIVES OF 4, 4-DISUBSTITUTED-3, 4-DIHYDRO-2 (1H)-
QUINAZOLINONES AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2002079157, 2002, SCHERING CORP, ARYL OXIME-PIPERAZINES USEFUL AS CCR5
ANTAGONISTS
WO2002079194, 2002, SCHERING CORP, CCR5 ANTAGONISTS USEFUL FOR TREATING AIDS
WO2002085860, 2002, PFIZER, PYRAZOLE DERIVATIVES FOR TREATING HIV
WO2002087583, 2002, ISTITUTO SUPERIORE DI SANITA, USE OF INHIBITORS OF THE
PROTEASE OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) TO BLOCK CELL MIGRATION
AND/OR INVASION, TISSUE INFILTRATION AND OEDEMA FOR THE THERAPY OF DISEASES
ASSOCIATED THEREWITH
WO2002087585, 2002, ABBOTT LAB, COMPOSITIONS COMPRISING LOPINAVIR AND
METHODS FOR ENHANCING THE BIOAVAILABILITY OF PHARMACEUTICAL AGENTS
WO2008127291, 2008, LOS ALAMOS NATIONAL SECURITY, LLC, ADVANCED DRUG
DEVELOPMENT AND MANUFACTURING
WO2002094203, 2002, AVANIR PHARMACEUTICALS, INHIBITORS OF MACROPHAGE
MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
US20030138483, 2003, ABBOTT LAB, Soft elastic capsules and compositions
thereof
WO2002096395, 2002, ABBOTT LAB, SOFT ELASTIC CAPSULES COMPRISING RITONAVIR
AND/OR LOPINAVIR
WO2007047371, 2007, MICRODOSE TECHNOLOGIES INC, ORAL DOSAGE COMBINATION
PHARMACEUTICAL PACKAGING
US20020192273, 2002, LEC TEC CORPORATION, Therapeutic patch useful for the
treatment of hemorrhoids
DE10131036, 2003, JOHANN TEUBNER, Medicinal composition, useful for treating
infection with human immunodeficiency virus, comprises condurango bark,
guaiacum wood, dandelion leaves and roots, peppermint leaves and arnica
WO2003013424, 2003, MYRIAD GENETICS, INC, USE OF R-NSAID COMPOUNDS FOR
ANTI-HIV TREATMENT
WO2003005826, 2003, YOSHIMATSU, MICHIHARU, AQUEOUS TAR SOLUTION AND
TAR−CONTAINING COATING
WO2003006506, 2003, F. HOFFMANN-LA ROCHE AG, PROTEASE INHIBITOR CONJUGATES
AND ANTIBODIES USEFUL IN IMMUNOASSAY
WO2003013534, 2003, EPIDAUROS BIOTECHNOLOGIE AG, MEANS AND METHODS FOR
IMPROVED TREATMENT OF CANCER BASED ON CYP3A5
EP1281755, 2003, PFIZER, Variants of the human cyp2d6 gene
US20030082594, 2003, BAYER AG, System and method for analyzing resistance of
a pathogen to one or more treatments
WO2003014105, 2003, TOBIRA THERAPEUTICS, INC., BICYCLIC COMPOUND, PRODUCTION
AND USE AS HIV INHIBITORS
WO2003016306, 2009, JANSSEN PHARMACEUTICA NV, HIV INHIBITING PYRIMIDINES
DERIVATIVES
WO2003020716, 2003, SCHERING CORP, PIPERIDINE DERIVATIVES USEFUL AS CCR5
ANTAGONISTS
WO2003018045, 2003, TIANJIN FUSOGEN BIOTECH CO., LTD., A PHARMACEUTICAL
BEING USED FOR TREATING HIV INFECTION, THE COMPOSITION AND USES THEREOF
WO2003022252, 2003, INTELLIPHARMACEUTICS, INC., COMBINATORIAL TYPE
CONTROLLED RELEASE DRUG DELIVERY DEVICE
DE10145361, 2003, PARI GMBH, Sterile liquid composition for pulmonary
administration in aerosol form comprises a sparingly water-soluble drug in
the form of suspended particles of defined size
WO2003024932, 2003, BRISTOL MYERS SQUIBB PHARMA CO, BIS-AMINO ACID
SULFONAMIDES AS HIV PROTEASE INHIBITORS
WO2003024995, 2003, CHRONTECH PHARMA AB, MOLECULES THAT BLOCK VIRAL
INFECTIVITY AND METHODS OF USE THEREOF
WO2003035074, 2003, ONO PHARMACEUTICAL CO., DRUGS COMPRISING COMBINATION OF
TRIAZASPIRO[5,5]UNDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4
INHIBITOR AND/OR P-GLYCOPROTEIN INHIBITOR
WO2003035111, 2003, SCICLONE PHARMACEUTICALS, INC., ANTIRETROVIRAL
COMPOSITIONS COMPRISING THYMOSIN ALPHA PEPTIDES AND PROTEASE INHIBITORS
WO2003035077, 2003, ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI
S.P.A, N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV
INTEGRASE
WO2003037379, 2003, EVONIK DEGUSSA GMBH,, USE OF GRANULAR MATERIALS BASED ON
PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS
WO2007115132, 2007, GUILFORD F. TIMOTHY | SCHUMM BROOKE, RADIOPHARMACEUTICAL
IN SELF-FORMING LIPOSOMAL FORMULATION CAPABLE OF MULTIPATH ADMINISTRATION
INCLUDING OTHER INGREDIENTS
WO2003041694, 2003, ALCHEMY INTERNATIONAL, USE OF COMPOUNDS COMPRISING
IODINE, STRONTIUM AND ASCORBIC ACID AS WELL AS EITHER BISMUTH, ZINC OR
POTASSIUM IN THE TREATMENT OF AIDS
WO2003043602, 2003, DDS TECH CO., LTD, SOLID DISPERSIONS CONTAINING
SUBSTITUTED CYCLODEXTRIN AND INSOLUBLE DRUG AND THEIR PREPARATIONS
WO2004110401, 2004, LECTEC CORPORATION, INHALATION ANTIVIRAL PATCH
WO2003046559, 2003, XANTHUS LIFE SCIENCES, INC, INDIVIDUALIZATION OF THERAPY
WITH ANTIVIRAL AGENTS
WO2003053343, 2003, PROGENICS PHARM INC, NOVEL COMPOUNDS THAT ENHANCE
DIMERIZATION OF THE SUBUNITS OF HIV-1 REVERSE TRANSCRIPTASE HAVING MUTATIONS
ASSOCIATED WITH RESISTANCE TO NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
WO2003049746, 2003, TIBOTEC PHARM LTD, COMBINATION OF CYTOCHOME P>450<
DEPENDENT PROTEASE INHIBITORS
WO2003051361, 2003, CEDARS-SINAI MEDICAL CENTER, USE OF HIV-1 PROTEASE

INHIBITORS AND THEIR DERIVATIVES IN THE TREATMENT OF INFLAMMATION
WO2003051301, 2003, HEMISPHER BIOPHARMA, USE OF dsRNAs IN STRATEGIC
THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
WO2003057173, 2003, SEQUOIA PHARMACEUTICALS, BROAD SPECTRUM INHIBITORS
WO2003062238, 2003, BRISTOL MYERS SQUIBB PHARMA CO, TRICYCLIC 2-PYRIMIDONE
COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2003066028, 2003, DEPOMED, INC., MANUFACTURE OF ORAL DOSAGE FORMS
DELIVERING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS
WO2003066830, 2003, ADIMAB, LLC, HUMAN MONOCLONAL ANTIBODIES AGAINST
MEMBRANE PROTEINS
US7666419, 2010, ABBOTT LAB, Anti-CCR5 antibody
WO2003072766, 2003, PROGENICS PHARM INC, ANTI-CCR5 ANTIBODY
WO2003075010, 2003, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,
NON-PEPTIDE IMMUNOLOGIC TRACER PRECURSORS COMPRISING A TYROSYL-(X)N OR
LYSINE-(X)N TYROSINE MOTIF, METHOD FOR PREPARING SAME AND USES THEREOF
WO2003078438, 2003, BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS,
CARBAMATES AS HIV PROTEASE INHIBITORS
US20040197321, 2004, DIGESTIE CARE INC., Composition and method to prevent
or reduce diarrhea and steatorrhea in HIV patients
WO2003082241, 2003, RANBAXY LABORATORIES LIMITED, CLARITHROMYCIN
FORMULATIONS HAVING IMPROVED BIOAVAILABILITY
WO2003082248, 2003, RANBAXY LABORATORIES LIMITED, TASTE MASKED COMPOSITIONS
OF ERYTHROMYCIN A AND DERIVATIVES THEREOF
WO2004092162, 2004, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE
US20040019027, 2004, CITY OF HOPE, Method of treating cerebrotendinous
xanthomatosis
WO2005064008, 2005, GILEAD SCIENCES INC, METHOD AND COMPOSITIONS FOR
IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS
US7205413, 2007, CENTOCOR ORTHO BIOTECH INC., Solvates and polymorphs of
ritonavir and methods of making and using the same
WO2004041118, 2004, UMD, INC, THERAPEUTIC COMPOSITIONS FOR DRUG DELIVERY TO
AND THROUGH COVERING EPITHELIA
WO2003099851, 2003, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, METHODS
AND COMPOSITIONS FOR INHIBITING HIV REPLICATION
WO2003101481, 2003, ALS THERAPY DEVELOPMENT FOUNDATION, INC., TREATMENT OF
NEURODEGENERATIVE DISEASES USING PROTEASOME MODULATORS
WO2003105826, 2003, CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA, 'SOLUBLE
STABLE PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATION OF HIV PROTEASE
INHIBITORS AND A PROCESS FOR THE PREPARATION OF CONCENTRATED PHARMACEUTICAL
COMPOSITIONS FOR THE ADMINISTRATION OF HIV PROTEASE INHIBITORS.'
WO2004002410, 2004, BRISTOL MYERS SQUIBB PHARMA CO,
2,4-DISUBSTITUTED-PYRIDINE N-OXIDES USEFUL AS HIV REVERSE TRANSCRIPTASE
INHIBITORS
WO2004002428, 2004, CYTOVIA INC, DERIVATIVES OF GAMBOGIC ACID AND ANALOGS AS
ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
WO2004003512, 2004, MONOGRAM BIOSCIENCES, INC., COMPOSITIONS AND METHODS FOR
DETERMINING THE SUSCEPTIBILITY OF A PATHOGENIC VIRUS TO PROTEASE INHIBITORS
WO2004004711, 2004, BIOMERIEUX | INSTITUT NATIONAL DE LA SANTE ET DE LA
RECHERCHE MEDICALE , USE OF AT LEAST TWO ANTICANCER COMPOUNDS, ONE OF WHICH
AT LEAST MODULATES PROTEASOME ACTIVITY FOR MAKING A MEDICINE FOR CANCER
TREATMENT
WO2004005313, 2004, GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O., NOVEL
COMPOUNDS, COMPOSITIONS AS CARRIERS FOR STEROID/NON-STEROID
ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES
WO2004004658, 2004, POINT THERAPEUTICS, INC., METHODS AND COMPOSITIONS
RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS
WO2004006847, 2004, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
SELECTED ANTIBODIES AND DURAMYCIN PEPTIDES BINDING TO ANIONIC PHOSPHOLIPIDS
AND AMINOPHOSPHOLIPIDS AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER
EP1382692, 2004, F. HOFFMANN-LA ROCHE AG, Enzymatic assay of HIV protease
inhibitors
WO2004009073, 2004, DAEHWA PHARM. CO., LTD., P-GLYCOPROTEIN INHIBITOR
COMPRISING OCTILONIUM BROMIDE AS AN EFFECTIVE INGREDIENT
WO2004011019, 2004, CHARITE-UNIVERSITAETSMEDIZIN, USE OF A PROTEASOME
INHIBITOR IN THE TREATMENT OF FIBROTIC DISEASES
WO2004010937, 2004, INDIANA UNIVERSITY, METHOD OF TREATING CANCER
WO2004012732, 2004, CHARITE-UNIVERSITAETSMEDIZIN, USE OF A PROTEASOME
INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN A LOW-DOSE
PROTEASOME INHIBITOR THERAPY
WO2004013110, 2004, BRISTOL MYERS SQUIBB PHARMA CO,
4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINIONES USEFUL AS HIV REVERSE
TRANSCRIPTASE INHIBITORS
WO2004012699, 2004, TORRENT PHARMACEUTICALS LIMITED, MODIFIED RELEASE
COMPOSITION COMPRISING COATED MICRO MATRIY PARTICLES CONTAINING THE HIGH
SOLUBLE ACTIVE INGREDIENT AND A RELEASE CONTROLLING AGENT
WO2004012700, 2004, TORRENT PHARMACEUTICALS LIMITED, NOVEL DOSAGE FORM
US20040073259, 2004, CYGENE INC., Treatment of patients infected by disease
causing organisms or biological warfare agents using hyperthermia
WO2004022066, 2004, FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG, METHOD AND MEANS
FOR THE TREATMENT OF VASCULAR AND CARDIAC DISEASES
WO2004021969, 2004, MEDIVIR AB, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS
WO2004024683, 2004, UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,
COMPOSITIONS FOR INDUCING INCREASED LEVELS OF beta-CHEMOKINES AND METHODS OF
USE THEREFOR
WO2004029201, 2004, FRONTIER BIOTECHNOLOGIES CO., LTD., PEPTIDE DERIVATIVE
FUSION INHIBITORS OF HIV INFECTION
WO2006002248, 2006, NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SC |
PANACOS PHARMACEUTICALS, INC. | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL
HILL, MONOACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, PREPARATION
THEREOF AND USE THEREOF
WO2005011567, 2005, FOAMIX LTD, FOAM CARRIER CONTAINING AMPHIPHILIC
COPOLYMERIC GELLING AGENT
EP1418432, 2004, F. HOFFMANN-LA ROCHE AG, Method, assay, and kit for
quantifying hiv protease inhibitors
US7902203, 2011, ABBOTT LAB, Anti-infective agents
WO2004041818, 2004, ABBOTT LAB, ANTI-INFECTIVE AGENTS
WO2004041247, 2004, BIODELIVERY SCIENCES INTERNATIONAL, INC, GEODATE
DELIVERY VEHICLES
WO2007143433, 2007, SETAGON INC | UNIVERSITY OF VIRGINIA PATENT FOUNDATION,
NANOPOROUS STENTS WITH ENHANCED CELLULAR ADHESION AND REDUCED NEOINTIMAL
FORMATION
WO2004045519, 2004, MOUNT SINAI SCHOOL OF MEDICINE, INDUCTION OF APOPTOSIS
BY HIV-1 INFECTED MONOCYTIC CELLS
WO2004046309, 2004, POLARIS GROUP, METHODS FOR INHIBITING VIRAL REPLICATION
IN VIVO
WO2004052296, 2004, THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC |
EMORY UNIVERSITY, DIOXOLANE THYMINE AND COMBINATIONS FOR USE AGAINST 3TC/
AZT RESISTANT STRAINS OF HIV
WO2004052862, 2004, ONO PHARMACEUTICAL CO., NITROGEN-CONTAINING HETEROCYCLIC
COMPOUNDS AND MEDICINAL USE THEREOF
WO2004055163, 2004, CYTOVIA INC, SUBSTITUTED
1-BENZOYL-3-CYANO-PYRROLO[1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF
CASPASES AND INDUCERS OF APOPTOSIS
WO2004054581, 2004, GSK LLC, CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS
WO2004054974, 2004, GSK LLC, CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
WO2004055010, 2004, GSK LLC, CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS
WO2004055011, 2004, GSK LLC, HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS
WO2004055012, 2004, GSK LLC, INDANE COMPOUNDS AS CCR5 ANTAGONISTS
WO2004055016, 2004, GSK LLC, PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5
ANTAGONISTS
WO2004054586, 2004, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, USE OF A
COMBINATION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
(NNRTI) WITH AN INHIBITOR OF CYTOCHROME P450, SUCH AS PROTEASE INHIBITORS
WO2004060370, 2004, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, TREATMENT OF
HIV INFECTION THROUGH COMBINED ADMINISTRATION OF TIPRANAVIR AND CAPRAVIRINE
WO2004058253, 2004, CYTOVIA INC, 3,5-DISUBSTITUTED-[1,2,4]-OXADIAZOLES AND
ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE
THEREOF
WO2004056770, 2004, SCHERING CORP, PIPERIDINE DERIVATIVES USEFUL AS CCR5
ANTAGONISTS
WO2004056181, 2004, HIBERNATION THERAPEUTICS LIMITED, ORGAN PRECONDITIONING,
ARREST, PROTECTION, PRESERVATION AND RECOVERY (2)
US20050020580, 2005, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH,
Materials and methods for the prevention or treatment of apoptosis and
apoptosis-related diseases and conditions
WO2004064846, 2004, GILEAD SCIENCES INC, COMPOSITIONS AND METHODS FOR
COMBINATION ANTIVIRAL THERAPY
WO2004065563, 2004, DANA-FARBER CANCER INSTITUTE, INC., NDR KINASE
MODULATORS
WO2005113059, 2005, PANACOS PHARMACEUTICALS INC | THE UNIVERSITY OF NORTH
CAROLINA AT CHAPEL HILL, INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF
THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
US20050026902, 2005, PHARMACIA CORPORATION, Methods and compositions for the
treatment or prevention of human immunodeficiency virus and related
conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
WO2004074218, 2004, AVANIR PHARMACEUTICALS, INHIBITORS OF MACROPHAGE
MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
WO2004074257, 2004, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2005011709, 2005, YALE UNIVERSITY, ANTI-VIRAL NUCLEOSIDE ANALOGS AND
METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS
WO2005027855, 2005, JARROW FORMULAS, INC., METHODS FOR TREATMENT OF HIV OR
MALARIA USING COMBINATIONS OF CHLOROQUINE AND PROTEASE INHIBITORS
WO2004074270, 2004, PFIZER, INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT
RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
WO2004076687, 2004, UNIVERSITEIT UTRECHT HOLDING B.V, METHOD FOR DETERMINING
ANTIVIRAL ACTIVITY OF AHPS RELATED COMPOUNDS
WO2004084892, 2004, ABBOTT LAB, USE OF RITONAVIR FOR THE TREATMENT OF
UNCONJUGATED HYPERBILIRUBINEMIA
WO2004085406, 2004, F. HOFFMANN-LA ROCHE AG, BENZYL-PYRIDAZINONS AS REVERSE
TRANSCRIPTASE INHIBITORS
WO2004085411, 2004, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES
WO2004084876, 2004, RECEPTICON APS, USE OF COMPOUNDS FOR THE PREVENTION OF
DRUG-INDUCED CELL TOXICITY
WO2004087140, 2004, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, ANTIVIRAL
COMBINATION OF A DIPYRIDODIAZEPINONE AND A FURTHER ANTIRETROVIRAL COMPOUND
WO2004087139, 2004, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, ANTIVIRAL
COMBINATION OF TIPRANAVIR AND A FURTHER ANTIRETROVIRAL COMPOUND
WO2004091578, 2004, BIODELIVERY SCIENCES INTERNATIONAL, INC, NOVEL
ENCOCHLEATION METHODS, COCHLEATES AND METHODS OF USE
CA2425495, 2004, STEVEN J SOLDIN, ANTI-RETROVIRAL ANALYSIS BY MASS
SPECTROMETRY
WO2004098531, 2004, VIRXSYS CORPORATION, INCREASED TRANSDUCTION USING ABC
TRANSPORTER SUBSTRATES AND/OR INHIBITORS
WO2006089546, 2006, OSTEOLOGIX A/S, TABLETS COMPRISING A HIGH LOAD OF
STRONTIUM
WO2004101512, 2004, GSK LLC, NAPHTHYRIDINE INTEGRASE INHIBITORS
WO2005000405, 2005, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, P38
KINASE INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME
WO2004112724, 2004, VGX PHARMACEUTICALS, INC, COMPOSITIONS FOR AND METHODS
FOR TREATING HIV
WO2004112747, 2004, BAXTER INTERNATIONAL INC., METHOD FOR DELIVERING DRUGS
TO THE BRAIN
WO2006074147, 2006, MYREXIS, INC., COMPOUNDS AND THERAPEUTICAL USE THEREOF
WO2005004873, 2005, ICN PHARMACEUTICALS SWITZERLAND LTD, USE OF ANTIVIRALS
AGAINST INFLAMMATORY BOWEL DISEASES
WO2005004881, 2005, ICN PHARMACEUTICALS SWITZERLAND LTD, USE OF RIBOFURANOSE
DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES
WO2005010011, 2005, XENOPORT, INC., METHODS OF SYNTHESIS OF ACYLOXYALKYL
COMPOUNDS
WO2005009413, 2005, DEPOMED, INC., DUAL DRUG DOSAGE FORMS WITH IMPROVED
SEPARATION OF DRUGS
WO2005007681, 2005, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE
WO2005007656, 2005, VIROCHEM PHARMA INC, SPIRO COMPOUNDS AND METHODS FOR THE
MODULATION OF CHEMOKINE RECEPTOR ACTIVITY
WO2005007070, 2005, CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA, STABLE
PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATION OF HIV PROTEASE INHIBITORS
AND PROCESS FOR PREPARING A CONCENTRATE PHARMACEUTICAL COMPOSITION FOR THE
ADMINISTRATION OF HIV PROTEASE INHIBITORS
WO2007089745, 2007, SIGNATURE R & D HOLDINGS LLC, NOVEL COMPOUNDS WITH HIGH
THERAPEUTIC INDEX
WO2005012276, 2005, CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE |
UNIVERSITE DE PARIS SUD XI, INTERMEDIATE PRODUCTS OF THE SYNTHESIS OF
FLUORIZED INHIBITORS OF ASPARTIC PROTEASES
US20050031713, 2005, ALKERMES CONTROLLED THERAPEUTICS, Methods for
administering active agents to CYP3A4 sensitive patients
WO2005016386, 2005, MEDITECH RESEARCH LIMITED, IMPROVED THERAPEUTIC
PROTOCOLS
WO2005018611, 2005, K.U. LEUVEN RESEARCH & DEVELOPMENT, PARTICLE SIZE
REDUCTION OF BIOACTIVE COMPOUNDS
WO2005039551, 2005, ABBOTT LAB, SOLID PHARMACEUTICAL DOSAGE FORM
WO2006091529, 2006, ABBOTT LAB, A SOLID PHARMACEUTICAL DOSAGE FORMULATION
WO2005035525, 2005, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE
WO2005028502, 2005, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE
WO2005030790, 2005, PANACOS PHARMACEUTICALS INC | THE UNIVERSITY OF NORTH
CAROLINA AT CHAPEL HILL, NOVEL TRITERPENE DERIVATIVES, PREPARATION THEREOF
AND USE THEREOF
WO2005037196, 2005, CYTOVIA INC, SUBSTITUTED
2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF
CASPASES AND INDUCERS OF APOPTOSIS
WO2005037860, 2005, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE
WO2005037246, 2005, PARI GMBH, AQUEOUS AEROSOL PREPARATION
WO2005051419, 2005, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH, RETROVIRUS-LIKE PARTICLES AND RETROVIRAL
VACCINES
WO2005043118, 2005, VERTEX PHARMA, DRUG DISCOVERY METHOD
WO2005042020, 2005, VERTEX PHARMA, COMBINATIONS FOR HCV TREATMENT
WO2005042570, 2005, VERTEX PHARMA, HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS
WO2005042517, 2005, SCHERING CORP, BIPIPERIDINYL DERIVATIVES USEFUL AS
INHIBITORS OF CHEMOKINE RECEPTORS
US7812034, 2010, CITY OF HOPE, Method of using protease inhibitors for the
treatment of liposarcomas
WO2005051358, 2005, ALZA CORP, COMPOSITION AND METHOD FOR ENHANCING
BIOAVAILABILITY
WO2005054297, 2005, EASTMAN CHEMICAL COMPANY, CELLULOSE INTERPOLYMERS AND
METHOD OF OXIDATION
EP1542012, 2009, F. HOFFMANN-LA ROCHE AG, Antibodies for detecting efavirenz
US7834043, 2010, ABBOTT LAB, HIV Protease Inhibiting Compounds
WO2005058841, 2005, ABBOTT LAB, HIV PROTEASE INHIBITING COMPOUNDS
WO2005061450, 2005, ABBOTT LAB, HIV PROTEASE INHIBITING COMPOUNDS
WO2005061487, 2005, ABBOTT LAB, HIV PROTEASE INHIBITING COMPOUNDS
WO2005058248, 2005, BRISTOL MYERS SQUIBB PHARMA CO, A METHOD OF TREATING HIV
INFECTION IN ATAZANAVIR RESISTANT PATIENTS USING A COMBINATION OF ATAZANAVIR
AND ANOTHER PROTEASE INHIBITOR
WO2005060663, 2005, CYTOVIA INC, DERIVATIVES OF GAMBOGIC ACID AND ANALOGS AS
ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
WO2005062979, 2005, ARK DIAGNOSTICS, INC., IMMUNOASSAYS, HAPTENS, IMMUNOGENS
AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS
WO2005063213, 2005, BIODELIVERY SCIENCES INTERNATIONAL, INC, RIGID LIPOSOMAL
COCHLEATE AND METHODS OF USE AND MANUFACTURE
WO2005062952, 2005, THE J. DAVID GLADSTONE INSTITUTES, COMPOSITIONS AND
METHODS FOR MODULATING SIRTUIN ACTIVITY
CN1247554, 2006, XIAMEN UNIVERSITY, Process for synthesizing ritonavir
WO2005066131, 2005, MEDIVIR AB, NON-NUCLEOTIDE REVERSE TRANSCRIPTASE
INHIBITORS
WO2005077406, 2005, RYTEK, PROTEASE INHIBITORS FOR THE TREATMENT OF
DIGESTIVE PATHOLOGIES
US7445897, 2008, THE UNIVERSITY OF WASHINGTON, Novel sequence variants of
multi-drug resistance genes, MDR1 and MRP1, and recombinant cells expressing
MRP1 and MDR1 for assessment of drug penetration and disposition
WO2005072706, 2005, BAXTER INTERNATIONAL INC., NANOSUSPENSIONS OF
ANTI-RETROVIRAL AGENTS FOR INCREASED CENTRAL NERVOUS SYSTEM DELIVERY
WO2005082362, 2005, PFIZER, THERAPEUTIC COMBINATIONS
WO2005082364, 2005, PFIZER, COMPOSITIONS COMPRISING HIV PROTEASE INHIBITOR
AND CYTOCHROME P450 ENZYME ACTIVITY INHIBITOR
US7468274, 2008, THE JOHNS HOPKINS UNIVERSITY, Single cell analysis of HIV
replication capacity and drug resistance
US20050182105, 2005, BRISTOL MYERS SQUIBB PHARMA CO, Method of using
3-cyano-4-arylpyridine derivatives as modulators of androgen receptor
function
WO2005077969, 2005, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE
WO2005076892, 2005, MONOGRAM BIOSCIENCES, INC., METHOD FOR DETERMINING
REDUCED SUSCEPTIBILITY OF HIV TO PROTEASE INHIBITOR TREATMENT
WO2005077050, 2005, GSK LLC, HIV INTEGRASE INHIBITORS
WO2005079752, 2005, RUBICON RESEARCH PRIVATE LIMITED, CONTROLLED RELEASE
PHARMACEUTICAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY
WO2008070625, 2008, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC, SURFACE
TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL
WO2005082331, 2005, RANBAXY LABORATORIES LIMITED, EXTENDED RELEASE TABLETS
OF CLARITHROMYCIN
WO2005086871, 2005, CYTOKINE PHARMASCIENCES INC, COMPOUNDS, COMPOSITIONS AND
METHODS FOR INHIBITING OR TREATING HIV-1
WO2005097818, 2005, KECK GRADUATE INSTITUTE, AN ASSAY SYSTEM FOR SCREENING
PROTEASE INHIBITORS
WO2005090317, 2005, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2005102328, 2005, BRISTOL MYERS SQUIBB PHARMA CO, METHODS OF TREATING HIV
INFECTION
WO2005102391, 2005, BRISTOL MYERS SQUIBB PHARMA CO, COMBINATIONS FOR THE
TREATMENT OF AIDS OR HIV INFECTIONS
WO2005102392, 2005, BRISTOL MYERS SQUIBB PHARMA CO, METHODS OF TREATING HIV
INFECTION
WO2006057945, 2006, MERCK & CO INC, 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE
COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF
ALZHEIMER'S DISEASE
WO2005111112, 2005, NOVA FLUX BIOSCIENCES, INC, CELLULOSE AND ACRYLIC BASED
POLYMERS AND THE USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES
WO2005107742, 2005, YALE UNIVERSITY, NOVEL ANTIVIRAL HELIOXANTHIN ANALOGS
WO2005110428, 2005, SEQUOIA PHARMACEUTICALS, RESISTANCE-REPELLENT RETROVIRAL
PROTEASE INHIBITORS
WO2005111006, 2005, CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA,
RITONAVIR ANALOGOUS COMPOUND USEFUL AS RETROVIRAL PROTEASE INHIBITOR,
PREPARATION OF THE RITONAVIR ANALOGOUS COMPOUND AND PHARMACEUTICAL
COMPOSITION FOR THE RITONAVIR ANALOGOUS COMPOUND.
WO2005110411, 2005, TIBOTEC PHARM LTD, COMBINATIONS OF SUBSTITUTED
1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS
WO2005115469, 2005, CEDARS-SINAI MEDICAL CENTER, ESTROGEN MODULATION OF
IFN-GAMMA-MEDIATED CONDITIONS AND DISEASES
WO2005116081, 2005, GENVAULT CORPORATION, STABLE PROTEIN STORAGE AND STABLE
NUCLEIC ACID STORAGE IN RECOVERABLE FORM
WO2005121378, 2005, SAINT LOUIS UNIVERSITY, METHODS AND COMPOSITIONS FOR
VACCINATION
WO2009017767, 2009, ZARS PHARMA INC, COMPOSITIONS AND METHODS FOR DERMALLY
TREATING NEUROPATHY WITH MINOXIDIL
WO2005121145, 2005, F. HOFFMANN-LA ROCHE AG, HETEROCYCLIC ANTIVIRAL
COMPOUNDS
WO2005124563, 2005, CEPTOR CORPORATION, COMPOUNDS AND KITS FOR TREATING
MUSCLE DISORDERS AND METHODS OF USE THEREOF
WO2007008499, 2007, KANISA PHARMACEUTICALS INC | SIKIC BRANIMIR | HOTH
DANIEL | SOCKS DAVID | GLENN SCOTT | MARCELLETTI JOHN | WALSH MICHAEL J |
MULTANI PRATIK S, TREATMENT OF CANCER PATIENTS EXHIBITING ACTIVATION OF THE
P-GLYCOPROTEIN EFFLUX PUMP MECHANISM
WO2005122741, 2005, WASHINGTON UNIVERSITY, ANTIBODIES AGAINST WEST NILE
VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF
WO2006014282, 2006, ABBOTT LAB, PRODRUGS OF HIV PROTEASE INHIBITORS
WO2006005720, 2006, TIBOTEC PHARM LTD, COMBINATION OF ANTI-HIV REVERSE
TRANSCRIPTASE AND PROTEASE INHIBITORS
WO2006005529, 2006, AICURIS GMBH & CO. KG, PARAPOXVIRUSES IN COMBINATION
WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV/AIDS
WO2006010545, 2006, F. HOFFMANN-LA ROCHE AG, BENZYLTRIAZOLONE COMPOUNDS AS
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
WO2006022759, 2006, SCOLR PHARMA, INC., COMPRESSED COMPOSITE DELIVERY SYSTEM
FOR RELEASE-RATE MODULATION OF BIOACTIVES
WO2006020415, 2006, GSK LLC, CHEMICAL COMPOUNDS
WO2006023400, 2006, GSK LLC, CHEMICAL COMPOUNDS
WO2006027711, 2006, PIRAMAL LIFE SCIENCES LIMITED, PRODRUGS CONTAINING NOVEL
BIO-CLEAVABLE LINKERS
WO2006021456, 2006, NOVARTIS AG, COMBINATION COMPRISING A STAUROSPORINE AND
A CYP3A4 INHIBITOR
WO2006026703, 2006, GSK LLC, CHEMICAL COMPOUNDS
WO2006028229, 2006, FUJIFILM CORPORATION, BENZONAPHTHACENEGLYCOSIDE
DERIVATIVE AND USE THEREOF
WO2006026924, 2006, LI ZELIN | ZENG YUE | ZENG YI | ZENG XIN, THE USE OF
GINSENOSIDE IN THE TREATMENT OF AIDS
WO2006031825, 2006, MACROGENICS, INC., HUMANIZED ANTIBODIES AGAINST WEST
NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF
WO2006034001, 2006, BRISTOL MYERS SQUIBB PHARMA CO, METHODS OF TREATING HIV
INFECTION
WO2006046134, 2006, VIVALIS, METHOD OF SCREENING BY USING CONFORMATION
SENSITIVE PEPTIDES
WO2006030297, 2006, RANBAXY LABORATORIES LIMITED, TASTE MASKED GRANULES
COMPRISING CLARITHROMYCIN, HYDROCOLLOIDS AND A COATING
WO2006036816, 2006, GSK LLC, CHEMCIAL COMPOUNDS
WO2006035418, 2006, SIGMOID PHARMA LIMITED, COMBINATION PRODUCTS
WO2006037827, 2006, COLL FARMA S.L, SOLID PHARMACEUTICAL COMPOSITION
COMPRISING THE THIAZOLYL METHYL ESTER OF
[5S-(5R*,8R*,10R*,11R*)]-10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-[2-1(1-M
ETHYLETHYL)-4-THIAZOLYL]-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-2,4,7,12-TETRAA
ZATRIDECAN-13-OIC ACID AND PRE
WO2006039356, 2006, CYTOVIA INC, SUBSTITUTED
N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATOR OF CASPASES
AND INDUCERS OF APOPTOSIS
WO2006034643, 2006, BEIJING CENTURY HEALTH MEDICAL & PHARMACEUTICAL
DEVELOPMENT LTD, A TRADITIONAL CHINESE MEDICINE COMPOSITION WITH ANTI-HIV
ACTIVITY, PREPARATION, AND USE THEREOF
WO2006039488, 2006, VERTEX PHARMA, HCV NS3-NS4A PROTEASE INHIBITION
WO2006037418, 2006, LTS LOHMANN THERAPIE-SYSTEME AG, PHARMACEUTICAL
COMBINATION COMPRISING DESOXYPEGANINE AND CYP2D6 INHIBITORS
WO2006037335, 2006, RECEPTICON APS, USE OF COMPOUNDS FOR THE PREVENTION OF
DRUG-INDUCED CELL TOXICITY
WO2006041900, 2006, CYTOVIA INC, SUBSTITUTED
N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF
CASPASES AND INDUCERS OF APOPTOSIS
WO2006044968, 2006, ACHILLION PHARMACEUTICALS INC, COMBINATION THERAPY FOR
TREATING VIRAL INFECTIONS
WO2006050165, 2006, YOO SEO HONG, METHODS AND COMPOSITIONS FOR REDUCING
NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS
WO2006065377, 2006, THE J. DAVID GLADSTONE INSTITUTES, METHODS OF TREATING
LENTIVIRUS INFECTION
WO2006052452, 2006, CATALENT PHARMA SOLUTIONS, NON-GELATIN SOFT CAPSULE
SYSTEM
WO2006053255, 2006, MYREXIS, INC., NOVEL BETULIN DERIVATIVES, PREPARATION
THEREOF AND USE THEREOF
WO2006050930, 2006, XIGEN S.A,, CONJUGATE MOLECULE COMPOUNDS WITH ENHANCED
CELL UPTAKE ACTIVITY
WO2007061454, 2007, MEDA PHARMACEUTICALS INC., COMPOSITIONS COMPRISING
AZELASTINE AND METHODS OF USE THEREOF
WO2006057637, 2006, YOO SEO HONG, DRIED FORMS OF AQUEOUS SOLUBILIZED BILE
ACID DOSAGE FORMULATION: PREPARATION AND USES THEREOF
WO2006058920, 2006, PIERRE FABRE MEDICAMENT, USE OF OMEGA-3 FATTY ACID(S)
FOR TREATING HYPERCHOLESTEROLEMIA CAUSED BY ANTI-RETROVIRAL TREATMENT OF
HIV-INFECTED PATIENTS
WO2006060918, 2006, VIROCHEM PHARMA INC, NOVEL SPIROTROPANE COMPOUNDS AND
METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY
WO2006060919, 2006, VIROCHEM PHARMA INC, NOVEL SPIROTROPANE COMPOUNDS AND
METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY
WO2006076131, 2006, GSK LLC, CHEMICAL COMPOUNDS
WO2006065947, 2006, NIPPON ZOKI PHARMACEUTICAL CO., LTD., METHOD FOR
TREATMENT OF HIV INFECTION
WO2006066414, 2006, VIROCHEM PHARMA INC, HYDROXYDIHYDROPYRIDOPY
RAZINE-1,8-DIONES AND METHODS FOR INHIBITING HIV INTEGRASE
WO2009003669, 2009, 4 AZA IP NV | GILEAD SCIENCES INC,
PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL
TREATMENT
WO2006078876, 2006, UNIVERSITY OF ROCHESTER, COMPOSITIONS AND METHODS
RELATING TO MITOCHONDRIAL HYPERPOLARIZATION IN NEUROLOGICAL DISEASE
US20060172945, 2006, UNIVERSITY OF MARLYAND BIOTECHNOLOGY INSTITUTE, Human
neutrophil alpha-defensin 4 inhibition of HIV-1
WO2006091798, 2006, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH, VACCINES AND METHODS FOR PREVENTION AND
TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS
WO2006091534, 2006, SCHERING CORP, PIPERIDINYL PIPERIDINE DERIVATIVES USEFUL
AS INHIBITORS OF CHEMOKINE RECEPTORS
WO2006091692, 2006, SCHERING CORP, PIPERIDINYL PIPERAZINE DERIVATIVES USEFUL
AS INHIBITORS OF CHEMOKINE RECEPTORS
WO2006090264, 2006, RANBAXY LABORATORIES LIMITED, A PROCESS FOR THE
SYNTHESIS OF 2-AMINO-5-PROTECTED AMINO-3-HYDROXY-1, 6-DIPHENYLHEXANE OR A
SALT THEREOF - AN INTERMEDIATE FOR ANTIVIRAL DRUGS
WO2006090270, 2006, RANBAXY LABORATORIES LIMITED, ACID ADDITION SALT OF
2-ISOPROPYL-4-(((N-METHYL)AMINO)METHYL)THIAZOLE AND ITS?USE IN THE
PREPARATION OF RITONAVIR
WO2006096444, 2006, GSK LLC, CHEMICAL COMPOUNDS
WO2006104646, 2006, GSK LLC, HIV PROTEASE INHIBITORS
DE102005012681, 2006, LUTZ WEBER, New 1,5-dihydro-pyrrol-2-one compounds are
HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia,
multiple sclerosis, Alzheimer's disease, degenerative disease, viral
infection and cancer
WO2006101920, 2006, UNIVERSITY OF ROCHESTER, COMPOSITIONS AND METHODS
RELATED TO THE MANIPULATION OF ADENOSINE 2A RECEPTOR SIGNALING FOR THE
TREATMENT OF HIV ASSOCIATED NEURONAL DAMAGE
WO2006097323, 2006, WEBER LUTZ, TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE
TREATMENT OF CANCER
WO2006105374, 2006, CARTER ANDREW J, OPTIMIZING PHARMACODYNAMICS OF
THERAPEUTIC AGENTS FOR TREATING VASCULAR TISSUE
WO2008046052, 2008, FOURNIER LABORATORIES IRELAND LTD, PHARMACEUTICAL
FORMULATIONS
WO2006108828, 2006, TIBOTEC PHARM LTD, (1, 10B-DIHYDRO-2-(AMINOALKYL-
PHENYL)-5H-PYRAZ0L0 [1,5-C] [1,3] BENZ0XAZIN-5-YL) PHENYL METHANONE
DERIVATIVES AS HIV VIRAL REPLIATION INHIBITORS
WO2006108666, 2006, PROTEOSYS AG, MEFLOQUINE, NELFINAVIR AND SAQUINAVIR AS
NOVEL AGENTS FOR NEURODEGENERATIVE AND (NEURO-) INFLAMMATORY DISEASES
WO2006108556, 2006, PARI GMBH, PHARMACEUTICAL AEROSOL COMPOSITION
WO2006108879, 2006, TIBOTEC PHARM LTD, USE OF A SULFONAMIDE COMPOUND FOR
IMPROVING THE PHARMACOKINETICS OF A DRUG
WO2006114001, 2006, AMBRILIA BIOPHARMA INC., METHOD FOR IMPROVING
PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS
WO2006120495, 2006, ADVANCED SCIENTIFIC DEVELOPMENTS, PHARMACEUTICAL
COMPOSITION COMPRISING AN ANTIVIRAL AGENT, AN ANTITUMOUR AGENT OR AN
ANTIPARASITIC AGENT AND AN ACTIVE SUBSTANCE SELECTED FROM CARVEOL, THYMOL,
EUGENOL, BORNEOL AND CARVACROL
WO2006125042, 2006, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, METHOD FOR THE
TREATMENT OF DRUG-INDUCED SEXUAL DYSFUNCTION
WO2006130426, 2006, KEMIA, INC, MODULATORS OF CCR-5 ACTIVITY
WO2006130477, 2006, MONOGRAM BIOSCIENCES, INC., METHODS AND COMPOSITIONS FOR
DETERMINING RESISTANCE OF HIV-1 TO PROTEASE INHIBITORS
WO2006129276, 2006, RANBAXY LABORATORIES LIMITED, PROCESSES FOR THE
PREPARATION OF STABLE POLYMORPHIC FORM I OF RITONAVIR
WO2006129134, 2006, BIOALLIANCE PHARMA | CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE | ECOLE NORMALE SUPERIEURE DE CACHAN | UNIVERSITE DE PARIS,
SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV
INFECTION THERAPEUTIC AGENTS
WO2006133194, 2006, VGX PHARMACEUTICALS, INC, METHODS FOR TREATING VIRAL
INFECTION WITH ORAL OR INJECTIBLE DRUG SOLUTION
WO2006136175, 2006, LIFECYCLE PHARMA A/S, PHARMACEUTICAL COMPOSITIONS
COMPRISING TACROLIMUS AND A CYP3A4 INHIBITOR
WO2007002238, 2007, MICELL TECHNOLOGIES INC, DRUG/POLYMER COMPOSITE
MATERIALS AND METHODS OF MAKING THE SAME
WO2007002172, 2007, UNIVERSITY OF MASSACHUSETTS | MASSACHUSETTS INSTITUTE OF
TECHNOLOGY | UNIVERSITY OF MARYLAND, HIV-1 PROTEASE INHIBITORS
WO2007000234, 2007, BAYER AG, MOXIFLOXACIN THERAPEUTIC USE FOR TREATING
IMMUNE SYSTEM FUNCTIONAL DISTURBANCES
WO2007000779, 2007, PANACEA BIOTEC LTD, NOVEL PHARMACEUTICAL SUSTAINED
RELEASE COMPOSITIONS AND PROCESSES THEREOF
WO2007004236, 2007, KRISHNAN RAMU, IMPROVED DRUG OR PHARMACEUTICAL COMPOUNDS
AND A PREPARATION THEREOF
WO2007008780, 2007, GLOBEIMMUNE, INC., COMPOSITIONS AND METHODS FOR
ELICITING AN IMMUNE RESPONSE TO ESCAPE MUTANTS OF TARGETED THERAPIES
WO2007008539, 2007, GSK LLC, CHEMICAL COMPOUNDS
WO2007011833, 2007, SUNESIS PHARMACEUTICALS, INC. | MERCK SHARP & DOHME
CORP., SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF
ALZHEIMER'S DISEASE
WO2007015824, 2007, INTERMUNE INC | ARRAY BIOPHARMA INC, NOVEL MACROCYCLIC
INHIBITORS OF HEPATITIS C VIRUS REPLICATION
WO2007013047, 2007, RANBAXY LABORATORIES LIMITED, WATER-DISPERSIBLE
ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS
WO2007014920, 2007, TIBOTEC BVBA | MEDIVIR AB, MACROCYCLIC INHIBITORS OF
HEPATITIS C VIRUS
WO2007014921, 2007, TIBOTEC BVBA | MEDIVIR AB, MACROCYCLIC INHIBITORS OF
HEPATITIS C VIRUS
WO2007014918, 2007, TIBOTEC BVBA | MEDIVIR AB, MACROCYCLIC INHIBITORS OF
HEPATITIS C VIRUS
WO2007014922, 2007, TIBOTEC BVBA | MEDIVIR AB, MACROCYCLIC INHIBITORS OF
HEPATITIS C VIRUS
WO2007014924, 2007, TIBOTEC PHARM LTD, MACROCYCLIC INHIBITORS OF HEPATITIS C
VIRUS
WO2007014919, 2007, TIBOTEC PHARM LTD, MACROCYLIC INHIBITORS OF HEPATITIS C
VIRUS
WO2007014925, 2007, TIBOTEC PHARM LTD, MACROCYLIC INHIBITORS OF HEPATITIS C
VIRUS
WO2007014923, 2007, TIBOTEC PHARM LTD, MACROCYCLIC INHIBITORS OF HEPATITIS C
VIRUS
WO2007014926, 2007, TIBOTEC PHARM LTD, MACROCYCLIC INHIBITORS OF HEPATITIS C
VIRUS
WO2007016589, 2007, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES
WO2007019098, 2007, GSK LLC, HIV INTEGRASE INHIBITORS
WO2007019100, 2007, GSK LLC, HIV INTEGRASE INHIBITORS
WO2007019130, 2007, GSK LLC, HIV INTEGRASE INHIBITORS
WO2007025307, 2007, VERTEX PHARMA, INHIBITORS OF SERINE PROTEASES
WO2007027999, 2007, GSK LLC, CHEMICAL COMPOUNDS
WO2007033208, 2007, UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE, USE OF
INDIRUBIN AND ITS DERIVATIVES IN THE TREATMENTS OF HIV INFECTION AND HEART
FAILURE

US7785879, 2010, SCHERING CORP, Pregnane X receptor compositions, crystals
and uses thereof
WO2007035957, 2007, PATHOLOGICA LLC, METHODS FOR TREATING VIRAL INFECTIONS
USING POLYAMINE ANALOGS
WO2007034312, 2007, PFIZER, THERAPEUTIC COMPOUNDS
WO2007039463, 2007, F. HOFFMANN-LA ROCHE AG, NNRT INHIBITORS
WO2007042037, 2007, LIFECYCLE PHARMA A/S, TACROLIMUS COMBINATION PRODUCTS
WO2007094825, 2007, MUTUAL PHARMACEUTICAL COMPANY, METAXALONE PRODUCTS,
METHOD OF MANUFACTURE, AND METHOD OF USE
WO2007045572, 2007, F. HOFFMANN-LA ROCHE AG, N-PHENYL PHENYLACETAMIDE
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS
WO2007045573, 2007, F. HOFFMANN-LA ROCHE AG, PHENYL-ACETAMIDE NNRT
INHIBITORS
WO2007049265, 2007, PRENDERGAST PATRICK T, ANTI MINERALOCORTICOID THERAPY OF
INFECTION
US20070098802, 2007, HEWLETT-PACKARD COMPANY, Organic nanoparticles and
associated methods
WO2007056083, 2007, AMBRX INC, BIOSYNTHETIC POLYPEPTIDE FUSION INHIBITORS
WO2007056208, 2007, CYTOVIA INC, N-ARYLALKYL-THIENOPYRIMIDIN-4-AMINES AND
ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE
THEREOF
WO2007056214, 2007, CYTOVIA INC, N-ALKYL-N-ARYL-THIENOPYRIMIDIN-4-AMINES AND
ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE
THEREOF
WO2007056215, 2007, CYTOVIA INC, N-ARYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS
AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2007061529, 2007, SCIDOSE PHARMA INC, LYOPHILIZATION PROCESS AND PRODUCTS
OBTAINED THEREBY
WO2010033637, 2010, Z & Z MEDICAL HOLDINGS, INC, DISSOLUTION OF ARTERIAL
PLAQUE
WO2007060682, 2007, STRIDES ARCOLAB LTD, EFFERVESCENT GRANULAR FORMULATIONS
OF ANTIRETROVIRAL DRUGS
WO2007062528, 2007, MIGENIX CORP, POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN
TREATING VIRAL INFECTIONS
WO2007065016, 2007, AU JESSIE L S | WIENTJES GUILLAUME M, METHODS AND
COMPOSITIONS TO IMPROVE ACTIVITY AND REDUCE TOXICITY OF STENTS
WO2007065256, 2007, VIROCHEM PHARMA INC, NOVEL SPIROPIPERIDINE COMPOUNDS AND
METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY
WO2007068380, 2007, BAYER AG, DIARYL UREA FOR TREATING VIRUS INFECTIONS
WO2007068383, 2007, BAYER AG, DIARYL UREAS FOR TREATING VIRUS INFECTIONS
WO2007075377, 2007, CYTOKINETICS INC, CERTAIN CHEMICAL ENTITIES,
COMPOSITIONS AND METHODS
WO2007072503, 2007, PANACEA BIOTEC LTD, COMBINATIONS FOR MANAGING
INFLAMMATION AND ASSOCIATED DISORDERS
WO2007076372, 2007, UNIVERSITY OF ROCHESTER, TREATMENT OF NEUROAIDS USING
INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3
WO2007073583, 2007, THE UNIVERSITY OF SYDNEY, A METHOD OF TREATMENT AND
AGENTS USEFUL FOR SAME
WO2007079260, 2007, GILEAD SCIENCES INC | JAPAN TOBACCO INC, METHODS FOR
IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS
WO2007083316, 2007, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM, DELIVERY SYSTEM FOR ACTIVE AGENTS
WO2007087548, 2007, GSK LLC, CHEMICAL COMPOUNDS
WO2007087549, 2007, GSK LLC, CHEMICAL COMPOUNDS
WO2007086039, 2007, TRINITY COLLEGE DUBLIN, A METHOD OF PRODUCING POROUS
MICROPARTICLES
WO2007089906, 2007, BRIGHAM YOUNG UNIVERSITY | NATIONAL JEWISH MEDICAL AND
RESEARCH CENTER, CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF
USE
WO2007089907, 2007, BRIGHAM YOUNG UNIVERSITY | VANDERBILT UNIVERSITY,
CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
WO2007089030, 2007, JAPAN TOBACCO INC, USE OF
6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHO
XY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING
RETROVIRUS INFECTION
WO2007090721, 2007, EVONIK ROEHM GMBH, PHARMACEUTICAL COMPOSITIONS
CONTAINING MIXTURES OF POLYMERS AND ACTIVE AGENTS POORLY SOLUBLE IN WATER
WO2007092645, 2007, SCHERING CORP | VIROPHARMA INC | WYETH CORP, NOVEL HCV
INHIBITOR COMBINATIONS AND METHODS
EP1820493, 2007, PARI GMBH, Aerosols for sinunasal drug delivery
WO2008054454, 2008, TRANSTECH PHARMA INC, NITROGEN-CONTAINING HETEROCYCLE
DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS
ANTIVIRAL AGENTS
WO2007093515, 2007, F. HOFFMANN-LA ROCHE AG, HETEROCYCLIC ANTIVIRAL
COMPOUNDS
WO2007093520, 2007, F. HOFFMANN-LA ROCHE AG, HETERO-BYCYCLIC ANTIVIRAL
COMPOUNDS
WO2007097936, 2007, WYETH CORP, PROTEIN HYDROLYSATE EXCIPIENTS
WO2007098247, 2007, ACHILLION PHARMACEUTICALS INC, SUBSTITUTED TARAXASTANES
USEFUL FOR TREATING VIRAL INFECTIONS
WO2007100739, 2007, SCHERING CORP, CCR5 ANTAGONISTS USEFUL FOR TREATING HIV
WO2007103740, 2007, ARK DIAGNOSTICS, IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND
ANTIBODIES FOR ANTI-HIV THERAPEUTICS
WO2007103670, 2007, ABBOTT LAB, NOVEL COMPOUNDS THAT ARE USEFUL FOR
IMPROVING PHARMACOKINETICS
WO2007103934, 2007, ABBOTT LAB, COMPOSITIONS AND METHODS OF USE OF RITONAVIR
FOR TREATING HCV
WO2007106450, 2007, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC, DIKETO
ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT
HIV INTEGRASE IN COMBINATION THERAPY
WO2007111866, 2007, SCHERING CORP, COMBINATIONS OF HCV PROTEASE INHIBITOR(S)
AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO
WO2007112345, 2007, AMR TECHNOLOGY INC, USE OF CYCLOSPORIN ALKENE ANALOGUES
FOR PREVENTING OR TREATING VIRAL-INDUCED DISORDERS
WO2007112352, 2007, AMR TECHNOLOGY INC, USE OF CYCLOSPORIN ALKYNE/ALKENE
ANALOGUES FOR PREVENTING OR TREATING VIRAL-INDUCED DISORDERS
WO2007112357, 2007, AMR TECHNOLOGY INC, USE OF CYCLOSPORIN ALKYNE ANALOGUES
FOR PREVENTING OR TREATING VIRAL-INDUCED DISORDERS
WO2007126812, 2007, GILEAD SCIENCES INC, PROCESS FOR PREPARATION OF HIV
PROTEASE INHIBITORS
WO2007113856, 2007, RUBICON RESEARCH PRIVATE LIMITED, ORALLY DISINTEGRATING
TABLETS
WO2007115181, 2007, EASTMAN CHEMICAL COMPANY, COMPOUNDS EXHIBITING EFFLUX
INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF
WO2007117482, 2007, VITAE PHARMACEUTICALS INC , RENIN INHIBITORS
WO2007115381, 2007, K.U.LEUVEN RESEARCH & DEVELOPMENT, ENHANCING SOLUBILITY
AND DISSOLUTION RATE OF POORLY SOLUBLE DRUGS
WO2007120595, 2007, NOVARTIS AG, ORGANIC COMPOUNDS AND THEIR USES
WO2007121125, 2007, NOVARTIS AG, ORGANIC COMPOUNDS AND THEIR USES
WO2007121124, 2007, NOVARTIS AG, ORGANIC COMPOUNDS AND THEIR USES
WO2007133865, 2007, NOVARTIS AG, ORGANIC COMPOUNDS AND THEIR USES
WO2007119006, 2007, LABORATOIRES GOEMAR, NEW MEDICINES FOR TREATMENTS
AGAINST RETROVIRUSES
WO2007121418, 2007, GSK LLC, CHEMICAL COMPOUNDS
WO2007124383, 2007, OREGON HEALTH & SCIENCE UNIVERSITY,
1,1'-BINAPHTHYL-BASED INHIBITORS OF NAD+-DEPENDENT DEACETYLASE ACTIVITY AND
SIR2-FAMILY MEMBERS
WO2007124104, 2007, ZOGENIX INC, NEEDLE-FREE DELIVERY OF HIV THERAPEUTICS
WO2007127683, 2007, VORONKOV MICHAEL VICTOR | NEZHINSKY EFIM DAVID |
ISAKULYAN LEVON GEVORKOVICH | OCHERET DARIA ALEXANDROVNA, ADMINISTRATION OF
AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS
WO2007129274, 2007, MEDIVIR AB, COMBINATION THERAPY
WO2007128349, 2007, EVONIK DEGUSSA GMBH, USE OF ROLL COMPACTED PYROGENICALLY
PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS
WO2008073138, 2008, IRM LLC, TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND
THEIR USE AS HIV INTEGRASE INHIBITORS
WO2010065079, 2010, ALDER BIOPHARMACEUTICALS INC, ANTIBODIES TO IL-6 AND USE
THEREOF
WO2007146695, 2007, ENANTA PHARM INC, ACYCLIC OXIMYL HEPATITIS C PROTEASE
INHIBITORS
WO2007143847, 2007, VIROCHEM PHARMA INC, SPIROTROPANE COMPOUNDS
WO2007147884, 2007, TIBOTEC PHARM LTD, 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE
SULFONAMIDE HIV PROTEASE INHIBITORS
WO2008002924, 2008, ENANTA PHARM INC, QUINOXALINYL MACROCYCLIC HEPATITIS C
VIRUS SERINE PROTEASE INHIBITORS
US20080039428, 2008, MYRIAD PHARMACEUTICALS, INC, Antiretroviral combination
therapy
WO2008005276, 2008, DIRECTCONTACT LLC, MEDICAL DEVICE/DRUG DELIVERY SYSTEM
FOR THE HEALING OF WOUNDS AND THE PREVENTION OF INFLAMMATION AND DISEASE
WO2009020457, 2009, GSK LLC, CHEMICAL COMPOUNDS
WO2008005511, 2008, INTERMUNE INC | ARRAY BIOPHARMA Inc, NOVEL INHIBITORS OF
HEPATITIS C VIRUS REPLICATION
WO2009008989, 2009, GILEAD SCIENCES INC, MODULATORS OF PHARMACOKINETIC
PROPERTIES OF THERAPEUTICS
WO2008008120, 2008, FMC CORP, SOLID FORM
WO2008011045, 2008, CYTOVIA INC,
3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS
ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2008009689, 2008, ABBOTT LAB, PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING
COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME
WO2008010953, 2008, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC,
PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION
THERAPY
WO2008009613, 2008, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2008011116, 2008, GILEAD SCIENCES INC, AZA-PEPTIDE PROTEASE INHIBITORS
WO2008011117, 2008, GILEAD SCIENCES INC, ANTIVIRAL PROTEASE INHIBITORS
WO2008016522, 2008, GILEAD SCIENCES INC | KOREA RESEARCH INSTITUTE OF
CHEMICAL TECHNOLOGY, NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS
US20080045495, 2008, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
Treatment of Patients with Cystic Disease by Alteration of Fibrocystin
Proteolysis
US20080026040, 2008, HEWLETT-PACKARD COMPANY, Active agent-releasing dosage
forms
US20080026062, 2008, HEWLETT-PACKARD COMPANY, Pharmaceutical compositions
including nano-sized active agent
WO2008019289, 2008, ENANTA PHARM INC, TETRAZOLYL MACROCYCLIC HEPATITIS C
SERINE PROTEASE INHIBITORS
WO2008017867, 2008, CIPLA LTD, ANTIRETROVIRAL SOLID ORAL COMPOSITION
WO2008021733, 2008, ENANTA PHARM INC, TETRAZOLYL ACYCLIC HEPATITIS C SERINE
PROTEASE INHIBITORS
WO2008062429, 2008, PANACEA BIOTEC LTD, PARTICLES FOR DELIVERY OF ACTIVE
INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF
WO2008021456, 2008, CYTOVIA INC,
N-ARYL-5,7-DIHYDROFURO[3,4-D]PYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF
CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2008019968, 2008, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2008022242, 2008, EMISPHERE TECHNOLOGIES, INC, SYNTHESIS OF PROPYL PHENOXY
ETHERS AND USE AS DELIVERY AGENTS
WO2008022956, 2008, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, METHOD FOR
DETERMINING TRANSPORT ACTIVITY OF A TRANSPORT PROTEIN
EP1894559, 2008, PARI GMBH, Means to solubilise steroids for inhalation
WO2008029417, 2008, MATRIX LAB LTD, PHARMACEUTICAL FORMULATION FOR USE IN
HIV THERAPY
WO2008033389, 2008, NOVARTIS AG, ORGANIC COMPOUNDS AND THEIR USES
WO2008033466, 2008, COMBINATORX SINGAPORE PRE LTD, COMPOSITIONS AND METHODS
FOR TREATMENT OF VIRAL DISEASES
WO2008034039, 2008, NEXUSPHARMA INC, NOVEL TETRAHYDRO-ISOQUINOLINES
WO2008034731, 2008, F. HOFFMANN-LA ROCHE AG, OCTAHYDROPYRROLO [3, 4-C]
PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS
WO2008116165, 2008, NEXT SAFETY INC, METHODS AND SYSTEMS OF DELIVERING
MEDICATION VIA INHALATION
WO2008041176, 2008, RANBAXY LABORATORIES LIMITED, PROCESS FOR THE
PREPARATION OF FORM I AND FORM II OF RITONAVIR
WO2008073558, 2008, THE JOHNS HOPKINS UNIVERSITY, WATER-DISPERSIBLE ORAL,
PARENTERAL, AND TOPICAL FORMULATIONS FOR POORLY WATER SOLUBLE DRUGS USING
SMART POLYMERIC NANOPARTICLES
US20080124407, 2008, THE UNIVERSITY OF WASHINGTON, INHIBITING CYP3A4
INDUCTION
WO2008051039, 2008, SEEGENE INC, METHOD FOR DETECTING NUCLEOTIDE VARIATIONS
WO2008052737, 2008, F. HOFFMANN-LA ROCHE AG, IMMUNOCHEMICALLY EQUIVALENT HIV
DRUG ANALOGS
WO2008052770, 2008, CUREVAC GMBH, (BASE-)MODIFIED RNA FOR INCREASING THE
EXPRESSION OF A PROTEIN
WO2008057402, 2008, CYTOVIA INC, N-ARYL-ISOXAZOLOPYRIMIDIN-4-AMINES AND
RELATED COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND
THE USE THEREOF
WO2008055995, 2008, ALPHAPTOSE GMBH, METHODS AND COMPOSITIONS FOR DETECTING
RECEPTOR LIGAND MIMETICS
WO2008063493, 2008, THE TEXAS A & M UNIVERSITY SYSTEM, COMPOSITIONS AND
METHODS RELATED TO TOLL-LIKE RECEPTOR-3
WO2008067164, 2008, ABBOTT LAB, SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
WO2008060578, 2008, CYTOVIA INC, 3-ARYL-6-ARYL-[1,2,4]
TRIAZOLO[3,4-B][1,3,4] THIADIAZOLES AND RELATED COMPOUNDS AS ACTIVATORS OF
CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2008059046, 2008, TIBOTEC PHARM LTD, MACROCYCLIC INHIBITORS OF HEPATITIS C
VIRUS
WO2008062385, 2008, CILLIERS REGINALD ANTHONY | LOUBSER ALISTAIR SHAYNE,
ANTIRETROVIRAL DRUG RESISTANCE TESTING
WO2008071587, 2008, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2008090287, 2008, IPSEN PHARMA S.A.S., USE OF AT LEAST ONE BOTULISM
NEUROTOXIN FOR TREATING THE PAIN INDUCED BY THERAPEUTIC TREATMENTS FOR THE
AIDS VIRUS
WO2008077649, 2008, GILEAD SCIENCES INC, PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR
TREATING VIRAL INFECTONS
WO2008077650, 2008, GILEAD SCIENCES INC, PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR
TREATING VIRAL INFECTIONS
WO2008092006, 2008, CERNOFINA LLC, ANTIMICROBIAL COMPOSITIONS
WO2008097924, 2008, AVANIR PHARMACEUTICALS, PHARMACEUTICAL COMPOSITIONS
COMPRISING DEXTROMETHORPHAN ANALOGS FOR THE TREATMENT OF NEUROLOGICAL
DISORDERS
WO2008100867, 2008, INTERMUNE INC | ARRAY BIOPHARMA, INC., NOVEL INHIBITORS
HEPATITIS C VIRUS REPLICATION
WO2008153610, 2008, SCHERING CORP, USE OF IL-23 ANTAGONISTS FOR TREATMENT OF
INFECTION
WO2008098789, 2008, KTB TUMORFORSCHUNGSGESELLSCHAFT MBH, DUAL ACTING
PRODRUGS
WO2008101665, 2008, NOVARTIS AG, MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE
INHIBITORS
WO2008103899, 2008, AUSPEX PHARMACEUTICALS INC, PREPARATION AND UTILITY OF
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
WO2008109462, 2008, FARNAM COMPANIES INC, SUSTAINED RELEASE COMPOSITIONS
USING WAX-LIKE MATERIALS
WO2008109483, 2008, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS,
PARTICULATE DRUG DELIVERY
WO2008109154, 2008, METASTATIX INC, CHEMOKINE RECEPTOR MODULATORS
WO2008112156, 2008, METASTATIX INC, CHEMOKINE RECEPTOR MODULATORS
WO2008112289, 2008, NEKTAR THERAPEUTICS, OLIGOMER-PROTEASE INHIBITOR
CONJUGATES
WO2008113177, 2008, CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINE,
COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR
DERIVATIVES THEREOF AND USES THEREOF
WO2008113364, 2008, RECEPTICON APS, PREVENTION OF NEPHROTOXICITY III
WO2008118991, 2008, UNIVERSITY OF SOUTHERN CALIFORNIA, METHODS AND
COMPOSITIONS FOR INDUCING APOPTOSIS BY STIMULATING ER STRESS
WO2008119662, 2008, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2008122534, 2008, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2008129106, 2008, INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A,
NANOPARTICLES COMPRISING A CYCLODEXTRIN AND A BIOLOGICALLY ACTIVE MOLECULE
AND USES THEREOF
US20080260837, 2008, TRIAD GROUP, INC, Physically stable aqueous suspensions
of active pharmaceuticals
WO2008133982, 2008, LECTEC CORP | ROLF DAVID, ADHESIVE PATCH WITH AVERSIVE
AGENT
WO2008131505, 2008, LIBBS FARMACEUTICA LTDA,, OSMOTIC FORM FOR CONTROLLED
RELEASE OF ACTIVE PRINCIPLES
WO2008137779, 2008, INTERMUNE INC | ARRAY BIOPHARMA INC, NOVEL MACROCYCLIC
INHIBITORS OF HEPATITIS C VIRUS REPLICATION
WO2008141227, 2008, INTERMUNE INC | ARRAY BIOPHARMA INC, NOVEL PEPTIDE
INHIBITORS OF HEPATITIS C VIRUS REPLICATION
WO2008140459, 2008, FMC CORP, SOLID FORM
WO2008140460, 2008, FMC CORP, SOLID FORM
WO2008140461, 2008, FMC CORP, SOLID FORM
US20080286343, 2008, FMC CORP, Solid form
US20080286344, 2008, FMC CORP, Solid form
US20080311162, 2008, FMC CORP, Solid form
WO2008145606, 2008, TIBOTEC PHARM LTD, NEW MUTATIONAL PROFILE IN HIV-1 GAG
CLEAVAGE SITE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE
WO2008145562, 2008, F. HOFFMANN-LA ROCHE AG, NON-NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
WO2008145733, 2008, UNIVERSITAET LEIPZIG, NOVEL CHEMICAL COMPOUNDS,
PRODUCTION THEREOF, AND USE THEREOF
WO2008154271, 2008, GSK LLC, CHEMICAL COMPOUNDS
WO2008149228, 2008, AUROBINDO PHARMA LTD, AN IMPROVED PROCESS FOR THE
PREPARATION OF SUBSTANTIALLY PURE
(2S,3S,5S)-5-AMINO-2-N,N-DIBENZYLAMINO-3-HYDROXY-1,6-DIPHENYLHEXANE
WO2008156632, 2008, CONCERT PHARMACEUTICALS INC, AZAPEPTIDE DERIVATIVES
WO2008157273, 2008, GSK LLC, CHEMICAL COMPOUNDS
WO2008157330, 2008, GSK LLC, CHEMICAL COMPOUNDS
WO2009002821, 2008, BRISTOL MYERS SQUIBB PHARMA CO, TABLETED COMPOSITIONS
CONTAINING ATAZANAVIR
WO2009002823, 2008, BRISTOL MYERS SQUIBB PHARMA CO, TABLETED COMPOSITIONS
CONTAINING ATAZANAVIR
WO2009002826, 2008, BRISTOL MYERS SQUIBB PHARMA CO, TABLETED COMPOSITIONS
CONTAINING ATAZANAVIR
WO2009002829, 2008, BRISTOL MYERS SQUIBB PHARMA CO, TABLETED COMPOSITIONS
CONTAINING ATAZANAVIR
WO2009000663, 2008, F. HOFFMANN-LA ROCHE AG, UREA AND CARBAMATE DERIVATIVES
AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
WO2009006199, 2009, GILEAD SCIENCES INC, THERAPEUTIC COMPOSITIONS AND THE
USE THEREOF
WO2009006203, 2009, GILEAD SCIENCES INC, THERAPEUTIC COMPOSITIONS AND THE
USE THEREOF
WO2009005693, 2009, GILEAD SCIENCES INC | KOREA RESEARCH INSTITUTE OF
CHEMICAL TECHNOLOGY, NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS
DE102007030695, 2009, SCICONCEPT GMBH, Co-crystal, useful e.g. to prepare a
pharmaceutical formulation for the treatment of psychosis, neurological
disorder and struma lymphomatosa, comprises an amino compound and urea as
further component
WO2009009531, 2009, CONCERT PHARMACEUTICALS INC, NOVEL PYRIMIDINECARBOXAMIDE
DERIVATIVES
WO2009014638, 2009, PROGENICS PHARM INC, METHODS OF INHIBITING INFECTION BY
DIVERSE SUBTYPES OF DRUG-RESISTANT HIV-1
IN01730CH2007, 2009, MATRIX LABORATORIES LTD ;, [EN]PHARMACEUTICAL
FORMULATION CONTAINING RITONAVIR
WO2009027644, 2009, SLOTERVAART PARTICIPATIES BV | STICHTING HET NEDERLANDS
KANKER INSTITUUT, COMPOSITION
WO2009035662, 2009, CONCERT PHARMACEUTICALS INC, DEUTERATED 4 -OXOQUINOLINE
DERIVATIVES FOR THE TREATMENT OF HIV INFECTION
WO2009038663, 2009, SCHERING CORP, METHOD OF TREATING HEPATITIS C PATIENTS
WO2009036341, 2009, THE REGENTS OF THE UNIVERSITY OF MICHIGAN, COMPOSITIONS
AND METHODS RELATING TO HIV PROTEASE INHIBITION
WO2009037855, 2009, NIHON KODOIRYO KENKYUKAI CO LTD, ORAL AND SKIN
COMPOSITIONS
WO2009040818, 2009, SOLUBEST LTD, COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE
COMPOUNDS AND METHOD FOR THEIR PREPARATION
WO2009042960, 2009, MICRODOSE TECHNOLOGIES INC, ORAL DOSAGE COMBINATION
PHARMACEUTICAL PACKAGING
WO2009043296, 2009, LIAONING LIFENG SCIENTIFIC & TECHNOLOGY DEVELOPMENT
COMPANY LTD, GAMBOGIC GLYCOSIDE DERIVATIVES AND ANALOGS, THE PREPARATION AND
THE APPLICATION THEREOF
WO2009045975, 2009, EMORY UNIVERSITY, POTENT COMBINATIONS OF ZIDOVUDINE AND
DRUGS THAT SELECT FOR THE K65R MUTATION IN THE HIV POLYMERASE
WO2009047264, 2009, NOVARTIS AG, SPIROPYRROLIDINES AND THEIR USE AGAINST HCV
AND HIV INFECTION
WO2009051782, 2009, CONCERT PHARMACEUTICALS INC, DEUTERATED ETRAVIRINE
WO2009051840, 2009, YALE UNIVERSITY, COMPOSITIONS AND METHODS FOR REDUCING
HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION
WO2009053828, 2009, ENANTA PHARM INC, P3 HYDROXYAMINO MACROCYCLIC HEPATITIS
C SERINE PROTEASE INHIBITORS
US20090105791, 2009, NEUROPHYSIOLOGICAL CONCEPTS LLC, LIGHT EMITTING MEDICAL
GARMENT DEVICE, KIT AND METHOD OF USING
WO2009055006, 2009, CONCERT PHARMACEUTICALS INC, DEUTERATED DARUNAVIR
US20090123425, 2009, ENANTA PHARM INC, MACROCYCLIC, PYRIDAZINONE-CONTAINING
HEPATITIS C SERINE PROTEASE INHIBITORS
WO2009056818, 2009, CIPLA LTD, NOVEL ANTIRETROVIRAL COMBINATION
WO2009058919, 2009, GSK LLC, CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
WO2009058921, 2009, GSK LLC, CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
WO2009058923, 2009, GSK LLC, CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
WO2009058924, 2009, GSK LLC, CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
WO2009059243, 2009, THE UAB RESEARCH FOUNDATION, TREATING AND PREVENTING
VIRAL INFECTIONS
WO2009092897, 2009, INSTITUT PASTEUR | CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE
MEDICALE), COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION
WO2009061856, 2009, SALK INSTITUTE FOR BIOLOGICAL STUDIES, NON-NUCLEOSIDE
REVERSE TRANSCRIPTASE INHIBITORS
US20090149491, 2009, ENANTA PHARM INC, CARBOCYCLIC OXIME HEPATITIS C VIRUS
SERINE PROTEASE INHIBITORS
WO2009064975, 2009, ENANTA PHARM INC, QUINOXALINE-CONTAINING COMPOUNDS AS
HEPATITIS C VIRUS INHIBITORS
WO2009076173, 2009, ENANTA PHARM INC, FLUORINATED TRIPEPTIDE HCV SERINE
PROTEASE INHIBITORS
WO2009076195, 2009, THE UNIVERSITY OF CHICAGO, TREATMENT OF DRUG-INDUCED
NAUSEA WITH OPIOID ANTAGONISTS
WO2009073843, 2009, CYTOTECH LABS, LLC, INHALABLE COMPOSITIONS HAVING
ENHANCED BIOAVAILABILITY
WO2009075960, 2009, GSK LLC, CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
WO2009079412, 2009, ARDEA BIOSCIENCES INC, REVERSE TRANSCRIPTASE INHIBITORS
WO2009082448, 2009, THE TEXAS A & M UNIVERSITY SYSTEM, MODIFIED
OLIGONUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C INFECTION
WO2009084036, 2009, MATRIX LAB LTD, COMPOSITION FOR TREATMENT OF VIRAL
INFECTIONS
WO2009080534, 2009, F. HOFFMANN-LA ROCHE AG, HETEROCYCLIC ANTIVIRAL
COMPOUNDS
WO2009081174, 2009, CIPLA LTD, ANTI - RETROVIRAL COMBINATION
WO2009083042, 2009, VAN TELLINGEN OLAF, METHODS AND MEANS FOR THE TREATMENT
OF CANCER
WO2009115652, 2009, UNIVERSITE DE LA MEDITERANNEE, AIX-MARSEILLE II,
COMPOSITION AND METHODS USED DURING ANTI-HIV TREATMENT
WO2009082818, 2009, VIROCHEM PHARMA INC, NOVEL C-21-KETO LUPANE DERIVATIVES
PREPARATION AND USE THEREOF
WO2009082819, 2009, VIROCHEM PHARMA INC, NOVEL LUPANE DERIVATIVES
WO2009088719, 2009, GILEAD SCIENCES INC, INHIBITORS OF CYTOCHROME P450
WO2009089263, 2009, ARDEA BIOSCIENCES INC, NOVEL COMPOSITIONS AND METHODS OF
USE
WO2009089295, 2009, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS
REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUM, ANTI-HIV DOMAIN
ANTIBODIES AND METHOD OF MAKING AND USING SAME
WO2009094205, 2009, CYTOVIA INC,
3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AND ANALOGS AS
ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2009094443, 2009, ENANTA PHARM INC, DIFLUORINATED TRIPEPTIDES AS HCV
SERINE PROTEASE INHIBITORS
WO2009094190, 2009, CHIMERIX INC, METHODS OF TREATING VIRAL INFECTIONS
US20090318519, 2009, KATHOLIEKE UNIVERSITEIT LEUVEN, PROCESS FOR RELEASE OF
BIOLOGICALLY ACTIVE SPECIES
WO2009098469, 2009, BIOSUSPENSIONS LTD, NOVEL COMPOSITIONS AND USES THEREOF
WO2009097670, 2009, NUNES ISEU DA SILVA, COMBINATION OF IMMUNOMODULATOR AND
ANTI-PATHOGENIC AGENT
WO2009102487, 2009, OXYGEN BIOTHERAPEUTICS INC | VIRGINIA COMMONWEALTH
UNIVERSITY, GAS BASED WOUND AND TISSUE THERAPEUTICS
WO2009105430, 2009, THE REGENTS OF THE UNIVERSITY OF MINNESOTA, TREATING
CANCER WITH DESTHIAZOLYL RITONAVIR
WO2009105774, 2009, SEQUOIA PHARMACEUTICALS, AMINO ACID INHIBITORS OF
CYTOCHROME P450
WO2009105776, 2009, SEQUOIA PHARMACEUTICALS, DIAMIDE INHIBITORS OF
CYTOCHROME P450
WO2009105781, 2009, SEQUOIA PHARMACEUTICALS, METHODS FOR INHIBITING DRUG
DEGRADATION
WO2009108865, 2009, ABBOTT LAB, TABLETS AND PREPARATION THEREOF
WO2009111638, 2009, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | BAXTER
INTERNATIONAL INC., COMPOSITIONS AND METHODS FOR DRUG DELIVERY
WO2009145956, 2009, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW
YORK, USES OF CALPAIN INHIBITORS TO INHIBIT INFLAMMATION
WO2009111040, 2009, LECTEC CORP, HAND SANITIZING PATCH
IN00496MUM2008, 2009, MACLEODS PHARMACEUTICALS LTD ;, NOVEL PROCESS FOR
MANUFACTURE OF LOPINAVIR AND RITONAVIR TABLETS
WO2009117596, 2009, ONTHERIX INC, ADAPTIVE BIOCHEMICAL SIGNATURES
WO2009117594, 2009, ENANTA PHARM INC, FLUORINATED MACROCYCLIC COMPOUNDS AS
HEPATITIS C VIRUS INHIBITORS
WO2009123768, 2009, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NANOCARRIER
AND NANOGEL COMPOSITIONS
WO2009121997, 2009, INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A,
PEGYLATED NANOPARTICLES CONTAINING A BIOLOGICALLY ACTIVE MOLECULE AND USE
THEREOF
WO2009126293, 2009, YALE UNIVERSITY | UNIVERSITY OF CAPE TOWN, POTENT
CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE
WO2009134616, 2009, INTERMUNE INC, NOVEL INHIBITORS OF HEPATITIS C VIRUS
REPLICATION
WO2009142842, 2009, INTERMUNE INC, NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS
C VIRUS REPLICATION
WO2009128947, 2009, CONCERT PHARMACEUTICALS INC, PIPERAZINE DERIVATIVES
WO2009129470, 2009, NANOBIO CORP, METHODS FOR TREATING HERPES VIRUS
INFECTIONS
WO2009134120, 2009, ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM, MASS
SPECTROMETRIC ANALYSIS OF SMALL MOLECULE ANALYTES
WO2009134401, 2009, PROGENICS PHARM INC, METHODS OF INHIBITING INFECTION BY
DIVERSE SUBTYPES OF DRUG-RESISTANT HIV-1
WO2009134987, 2009, ENANTA PHARM INC, DIFLUOROMETHYL-CONTAINING MACROCYCLIC
COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
US20100021427, 2010, TIANJIN FUSOGEN PHARMACEUTICALS, INC, Use of Antiviral
Peptides For Treatment of Infections Caused by Drug-Resistant HIV
WO2009153654, 2009, AUROBINDO PHARMA LTD, SOLID DOSAGE FORMS OF
ANTIRETROVIRALS
CN101613325, 2009, CUICENG YE, Process for producing 5-hydroxymethylthiazole
WO2010089763, 2010, RELIANCE LIFE SCIENCES PVT LTD, POLY(N-VINYL
CAPROLACTAM-CO-ACRYLAMIDE) MICROPARTICLES FOR CONTROLLED RELEASE
APPLICATIONS
WO2010000459, 2010, CENTOCOR ORTHO BIOTECH INC., CYCLOPROPYL POLYMERASE
INHIBITORS
WO2010009335, 2010, MICELL TECHNOLOGIES INC, DRUG DELIVERY MEDICAL DEVICE
WO2010014130, 2010, DIGESTIVE CARE INC, COMPOSITION AND METHOD TO PREVENT OR
REDUCE DIARRHEA AND STEATORRHEA IN HIV PATIENTS
WO2010012466, 2010, GANIAL IMMUNOTERAPEUTICS INC, ANTITUMOR PROPERTIES OF NO
MODIFIED PROTEASE INHIBITORS
WO2010017432, 2010, SCHERING CORP, PHARMACEUTICAL FORMULATIONS OF AN HCV
PROTEASE INHIBITOR IN A SOLID MOLECULAR DISPERSION
US20100041014, 2010, SEARETE LLC, Biological targeting compositions and
methods of using the same
US20100056622, 2010, LAUTERBACH EDWARD C, Methods of Using Ramelteon to
Treat Patients Suffering from a Variety of Neurodegenerative Diseases
US20100068786, 2010, PURDUE RESEARCH FOUNDATION, METHODS AND COMPOSITIONS
FOR REVERSING P-GLYCOPROTEIN MEDICATED DRUG RESISTANCE
WO2010033614, 2010, SEQUOIA PHARMACEUTICALS, STABLE SOLID ORAL DOSAGE
CO-FORMULATIONS
WO2010038237, 2010, RUBICON RESEARCH PRIVATE LIMITED, COMPOSITIONS
EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT
WO2010037566, 2010, CAPSULUTION PHARMA AG, IMPROVED NANOPARTICULATE
COMPOSITIONS OF POORLY SOLUBLE COMPOUNDS
WO2010037402, 2010, DAKO DENMARK A/S, MOLECULAR VACCINES FOR INFECTIOUS
DISEASE
WO2010041241, 2010, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM LTD, HIV-1 INTEGRASE DERIVED PEPTIDES AND
COMPOSITIONS
WO2010045266, 2010, INTERMUNE INC, THERAPEUTIC ANTIVIRAL PEPTIDES
WO2010047819, 2010, CONCERT PHARMACEUTICALS INC, HYDROXYETHYLAMINO
SULFONAMIDE DERIVATIVES
WO2010057048, 2010, CALISTOGA PHARMACEUTICALS, INC., THERAPIES FOR
HEMATOLOGIC MALIGNANCIES
US20100135960, 2010, ENANTA PHARM INC, ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES
WO2010059883, 2010, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, DEGRADABLE
HYDROGEL COMPOSITIONS AND METHODS
WO2010065118, 2010, SEARETE LLC, ANTI-INFLAMMATORY COMPOSITIONS AND METHODS
WO2010077734, 2010, CYTOKINE PHARMASCIENCES INC, NOVEL ANTIVIRAL COMPOUNDS,
COMPOSITIONS, AND METHODS OF USE
WO2010077740, 2010, CYTOKINE PHARMASCIENCES INC, NOVEL ANTIVIRAL COMPOUNDS,
COMPOSITIONS, AND METHODS OF USE
WO2010068899, 2010, CREIGHTON UNIVERSITY, NANOPARTICLES COMPRISING
COMBINATIONS OF ANTIRETROVIRAL AGENTS AND USE THEREOF
WO2010075065, 2010, BANNER PHARMACAPS INC, METHODS FOR ENHANCING THE RELEASE
AND ABSORPTION OF WATER INSOLUBLE ACTIVE AGENTS
WO2010077317, 2010, AMPLYX PHARMACEUTICALS INC, PROTEASE INHIBITORS
US20100160262, 2010, THE J. DAVID GLADSTONE INSTITUTES, COMPOSITIONS AND
METHODS FOR MODULATING SIRTUIN ACTIVITY
CN101440091, 2009, XIAMEN UNIVERSITY, Ritonavir water-soluble derivatives,
synthesizing method and use thereof
WO2010077061, 2010, HANALL BIOPHARMA CO., LTD, PHARMACEUTICAL FORMULATIONS
CONTAINING ANTIVIRAL DRUGS
WO2010089767, 2010, PANACEA BIOTEC LTD, DUAL RELEASE PHARMACEUTICAL
SUSPENSION
US7906519, 2011, MUTUAL PHARMACEUTICAL COMPANY, Methods for Concomitant
Administration of Colchicine and a Second Active Agent
WO2010086844, 2010, MAPI PHARMA HK LTD, POLYMORPHS OF DARUNAVIR
WO2010091413, 2010, ENANTA PHARM INC, LINKED DIBENZIMIDAZOLE DERIVATIVES
WO2010096462, 2010, ENANTA PHARM INC, LINKED DIIMIDAZOLE DERIVATIVES
WO2010099527, 2010, ENANTA PHARM INC, HEPATITIS C VIRUS INHIBITORS
WO2010099458, 2010, INTERMUNE INC | F. HOFFMANN-LA ROCHE AG | PHARMASSET,
INC, COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC
PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER
FIBROSIS AND IMPAIRED LIVER FUNCTION
WO2010100381, 2010, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
UNIVERSITE DE STRASBOURG | UNIVERSITE DE LA MEDITERRANEE, NOVEL ANTIVIRAL
AGENT
WO2010107831, 2010, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NANOCARRIER
COMPOSITIONS AND METHODS
WO2010111238, 2010, MICELL TECHNOLOGIES INC, IMPROVED BIODEGRADABLE POLYMERS
WO2010115981, 2010, NOVARTIS AG, 7-AZADISPIRO [3.0.4.1]
DECANE-8-CARBOXAMIDES AS HEPATITIS C VIRUS INHIBITORS
WO2010116248, 2010, NOVARTIS AG, ORGANIC COMPOUNDS AND THEIR USES
US20100261731, 2010, ABBOTT LAB, Method for Treating a Disease, Disorder or
Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1
Substrate
WO2010121351, 2010, THERATECHNOLOGIES INC, USE OF (HEXENOYL
TRANS-3)HGRF(1-44)NH2 AND RITONAVIR IN COMBINATION THERAPY
WO2010122087, 2010, F. HOFFMANN-LA ROCHE AG, METHODS FOR IMPROVING
PHARMACOKINETICS
US20100273733, 2010, FABUNAN RUBEN G, HIV Treatment
WO2010127099, 2010, AMARIN CORP PLC, PHARMACEUTICAL COMPOSITIONS COMPRISING
EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME
WO2010127272, 2010, CONCERT PHARMACEUTICALS INC, HYDROXYETHYLAMINO
SULFONAMIDE DERIVATIVES
WO2010132494, 2010, GHOSH ARUN K, COMPOUNDS AND METHODS FOR TREATING AIDS
AND HIV INFECTIONS
WO2010132511, 2010, SANOFI, METHODS OF REDUCING THE RISK OF DRONEDARONE USE
IN CERTAIN PATIENT POPULATIONS
WO2010132663, 2010, CONCERT PHARMACEUTICALS INC, PEGYLATED AZAPEPTIDE
DERIVATIVES AS HIV PROTEASE INHIBITORS
WO2010132163, 2010, ENANTA PHARM INC, MACROCYCLIC COMPOUNDS AS HEPATITIS C
VIRUS INHIBITORS
WO2010132664, 2010, BAXTER INTERNATIONAL INC., COMPOSITIONS AND METHODS FOR
DRUG DELIVERY
WO2010143207, 2010, RUBICON RESEARCH PRIVATE LIMITED, TASTE-MASKED ORAL
FORMULATIONS OF INFLUENZA ANTIVIRALS
WO2010144869, 2010, NEKTAR THERAPEUTICS, PROTEASE INHIBITORS
WO2010148006, 2010, ENANTA PHARM INC, HEPATITIS C VIRUS INHIBITORS
WO2010148323, 2010, WHITTEMORE PETERSON INSTITUTE FOR NEURO-IMMUNE DISEASE,
DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC
MURINE LEUKEMIA VIRUS
WO2010150100, 2010, ENTARCO SA, THE USE OF SPINOSYNS AND SPINOSYN
COMPOSITIONS AGAINST DISEASES CAUSED BY PROTOZOANS, VIRAL INFECTIONS AND
CANCER
WO2010151495, 2010, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC, MATERIALS
AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS


--
James Love.  Knowledge Ecology International
http://www.keionline.org, +1.202.332.2670, US Mobile: +1.202.361.3040,
Geneva Mobile: +41.76.413.6584, efax: +1.888.245.3140.  Sometimes I am using
my MaxRoam number: +447937390810
twitter.com/jamie_love
_______________________________________________
Ip-health mailing list
Ip-health at lists.keionline.org
http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

World Intellectual Property Organization Disclaimer:

This electronic message may contain privileged, confidential and
copyright protected information. If you have received this e-mail
by mistake, please immediately notify the sender and delete this
e-mail and all its attachments. Please ensure all e-mail attachments
are scanned for viruses prior to opening or using.




More information about the Ip-health mailing list